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Chapter I 
Summary 
Chronic hepatitis C is a slowly progressive liver disease that may evolve into cilThosis 
with its potential complications of liver failure or hepatocellular carcinoma. Current 
therapy with alpha-interferon is directed at viral clearance, but sllstained response is only 
achieved in 20-40% of patients without cirrhosis, and less than 20% in patients with 
cirrhosis who need therapy most. Treatment for those who do not respond to antiviral 
therapy is highly desirable. 
In Japan, glycyrrhizin has been used for more than 20 years as treatment for 
chronic hepatitis. In randomized controlled trials, glycYlThizin induccd a significant 
reduction of serum uminotransferases and improvement in JiveI' histology compared to 
placebo. Recently, these short-term effects have becn amplified by a well-conducted 
retrospective study suggesting that long-term usage of glycYlThizin prevents development 
of hepatocellular carcinoma in chronic hepatitis C. 
The mechanism by which glycyrrhizin improves liver biochemistry and histology are 
undefined. Metabolism, phannacokilletics, side-effects, antiviral and hepatoprotectivc 
effects of glycyrrhizin are discussed. 
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Introduction 
Chronic hepatitis C infection, usually a sub-clinical disease in its initial phase, can be 
associated with progressive liver disease that may evolve insidiously into cirrhosis and 
carries an increased risk of hepatocellular carcinoma (ReC).!,2 Spontaneous remission 
of viral replication is rare; therefore effective treatment is highly desirable. Treatment 
with alpha-interferon leads to serum alanine aminotransferase (ALT) normalization and 
HeV-RNA clearance in 20-40% of patients but relapses after treatment withdrawal are 
ti"equent.-' So different treatment strategies have to be sought for those who don't respond. 
These approaches might include viral activity reducing or hepatoprotective medication. 
In Japan glycynhizin. a natural compound extracted from the roots of G/ycyrrhiza glabra. 
has been used for more than 20 yeru's as a treatment for chronic hepatitis.4 Glycyrrhizin is 
a conjugate of one molecule of glycYll'hetinic acid with two molecules of glucuronic acid 
(Figure 1). It has been used for many centuries in the traditional Chinese medicine as an 
anti-allergic agent. Because of its sweet taste it is also used as a food additive, for example 
in beverages and licorice.' In 1946 Revers reported the anti-ulcer effect of licorice;' since 
then, glycynhizin was used for many years as anti-ulcer drug in Europe. In Japan, intrave-
nous gJycynhizin has been used for allergic diseases, mainly in the dermatological field. In an 
attempt to use glycyrrhizin as a treatment for "allergic" hepatitis it lowered the transaminases. 
In 1977 Suzuki et al. pelfonned a double blind randomized controlled trial in 133 cases 
with histologically documented chronic active liver disease.? The plasma transaminase activity 
improved significantly in the group treated with glycyrrhizin as compared to the placebo 
treated group. Hino et at. also found an improvement of the liver histology after treating 
chronic active hepatitis with glycyrrhizin.sThe mechanism by which glycyrrhizin improves the 
biochemistry and histology is unknown. This review will deal with the metabolism and phar-
macokinetics, the side-effects, the anti-viral and hepatoprotective action of glycyrrhizin. It will 
also discuss the long-term effects of glycynhizin in the treatment of cln'Onic viral hepatitis C. 
Methods 
Medline (1966 - May 1997) was used as a reference source with the key words: glycyr-
rhizin(e), glycyrrhizic acid, licorice and liquorice. The retrieved publications were supple-
mented with relevant articles found in the respective reference lists. 
Metabolism & Pharmacokinetics 
After oral administration glycyrrhizin is metabolized to glycyrrhetinic acid by intestinal 
bacteria which contain P-D-glucuronidase (Figure 1).9 After intravenous administration of 
3 
Chapter I 
glycyrrhizin, both glycyrrhizin and glycyrrhetinic acid appear in the plasma. Intravenously 
administered glycyrrhizin is metabolized in the liver by lysosomal P-D-glucuronidase 
to 3-mono-glucuronide-glycyrrhetinic acid. The human liver is not able to metabolize 
to 3-mono-glucul'Onide-glycyrrhetinic acid to glycYlThetinic acid; 3-mono-glucul'Onide-
glycyrrhetinic acid is excreted with bile into the intestine where bacteria metabolize it to 
glycyrrhetinic acid, which is re-absorbed,lO 
p-0·glucuronidase 
glycyrrhizin 
Metabolism of glycyrrhizin to glycyrrhetinic acid by P-O-glucuronidase 
Figure 1 
glycyrmetinic acid 
After intravenous injcction of glycyrrhizin in healthy volunteers the terminal half life 
(t.,) and the total body clearance (CI",,) were 2.7-4.8 hand 16-25 mL/kg/h, respectively. II 
After an 80 mg dose the maximum glycynhizin plasma concentration was 29.3 J.lg/mL; 
in this study glycYlThetinic acid was not detected in the plasma, probably because the 
detection limit of the assay for glycyrrhctinic acid (0.050 llg/mL) was too high. After oral 
administration of 100 mg glycyrrhizin in the same healthy volunteers no glycYlThizin was 
found in the plasma; glycyrrhetinic acid was found at < 0.2 fIg ImL. In the 24-hours period 
after oral administration, glycyrrhizin was excreted in urine, suggesting that glycyrrhizin 
is partly absorbed as intact drug, probably the detection limit of the assay for glycyrrhizin 
(0.5 flg/mL) was too high to determine the very small amounts of plasma glycyrrhizin. II 
The terminal half life and the total body clearance of glycYlThizin aftcr 120 mg intra-
venous glycyrrhizin in eight chronic hepatitis patients were 6.0 h (range 4.3-10.7 h) 
and 7.9 mLlkg/h (4.5 -12.7 mLlkg/h), respectively. Compared to healthy subjects the 
t., and the CI,o, were 2 and 0.7 times that of healthy subjects. The total body c1carance 
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was inversely correlated with the transaminases (AST r=-0.739 and ALT r=-0.783). This 
inverse correlation between Cl
tot 
and ALT and AST was also found in six cirrhosis patients. 
After improvement of the liver functions the t" shortened from 7.6 to 3,4 h. and the Cl", 
increased from 2.8 to 11,4 mLlkg/h. Thus, pharmacokinetic profiles after intravenous 
administration of glycyrrhizin are correlated with the functional capacity of the liver. [2, [J 
Side Effects 
Pseudo-aldosteronism, with sodium retention, hypokalemia and hypertension, is a well 
known side-effect of glycyrrhizin.14 Stewart (1987) ef al. concluded that glycyrrhizin's 
metabolite glycYlThetinic acid causes this phenomenon by inhibiting the enzyme 
llP-hydroxy-steroid-dehydrogenase (IIP-HSD) in the kidney.I' IIP-HSD exists as two 
isoforms. The renal isofol'ln II P-hydroxy-steroid-dehydrogenase converts cortisol to 
cortisone and the liver isoform catalyzes the reverse reaction. [6 Glycyrrhetinic acid does 
not inhibit the liver enzyme, but inhibits the renal ll-P-hydroxy-steroid-dehydrogenase. 17 
This leads to increased cortisol levels in the kidney. Because cortisol and aldosterone 
bind with the same affinity to the mineralocorticoid receptor, a raise of renal cortisol will 
result in a hypermineralocorticoid effect. 15 Stimulation of the mineralocorticoid receptor 
leads to sodium retention, suppression of renin production, and subsequently to diminished 
formation of angiotensin I and aldosterone (Figure 2).15 
Glycyrrhetinic Acid 
Cortisol ~ 'Cortisone. 
+ suppressIon 
. ..--" RAAS 
mlnera!o- ............- N 
corticoid ~ a 
receptor""""", retention 
~ Kexcretion 
Mechanism of side effects, Glycyrrhetinic add inhibits conversion of cortisol to cortisone. The surplus of <orlisol stimulates the 
miner alocor ticoid-receptor in the kidney, which causes suppression of the renin-angiotensin-aldosterone system (RAAS), sodiu m retention 
and kaHuresis. 
figure 2 
Table 1 shows the changes of plasma renin activity, aldosterone, sodium, potassium, 
cortisol and cortisone in plasma and urine during glycyrrhizin administration (225 rug/day 
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during 7 days) in eighteen volunteers,ls Plasma renin activity and aldosterone were sup-
pressed during glycyrrhizin administration and also their urinary excretion diminished 
significantly. Sodium was retained with no decrease in winary excretion. There was a 
kalillresis with a significant reduction of plasma potassium. Although the urinary excre-
tion of cortisol increased, plasma cortisol levels remained normal. Both plasma and 
urinary concentration of cortisone decreased. In this study no alteration of body weight 
and mean blood pressure were observed, although gain of body weight and hypertension 
arc common side-effects of glycynhizin.14 After glycyrrhizin withdrawal the effccts on 
electrolyte metabolism recovered after one week, plasma renin activity and aldosterone 
remained low for two to four months. !9, 20 
Tabl.l. 
Changes of plasma renin activity (PRA),aldosterone,sodium,potassium,corlisol and cortisone in plasma and urine during oral glycyrrhizin 
administration (225 mg I day for 7 days) 
Compound plasma urine 
PRA 1* n.d.t 
aldosterone 1 1 
sodium t:j: = § 
potassium 1 t 
cortisol t 
cortisone 1 1 
* significant decrease t not done 
t significant increase § no significant difference 
The incidence of side-effects is dose-dependent and differs among subjects: side 
effects occur more often in conditions favoring sodium retention, such as during the pre-
menstrual period or oral contraceptive use and m'e facilitated by subclinical diseases as 
borderline hypertension and high plasma renin activity.20.2:! 
Three case reports are mentioned in which severe hypokalemia « 2 mmo1!L) caused 
by excess licorice consumption induced cardiac arrhythmia; in one case it led to 
cardiac arrest. 22,23 Hypokalemia can also induce acute rhabdomyolysis with a clinical 
presentation of muscle weakness, paraparesis or quadriplegia. These symptoms totally 
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disappeared after cessation of licorice consumption and normalization of the potassium 
concentration.2.f-26 Patients using thiazide diuretics, which enhance potassium loss, are 
at risk of developing severe hypokalemia and should be monitored carefully during 
glycyrrhizin treatment. 
Pharmacological Effects 
Amiviral ~tfect 
[n 1977, Pompei et al. found that glycyrrhizin inhibited growth and cytopathology of 
herpes simplex virus type I in human aneuploid HEp2 cells. This antiviral effect was 
not mediated by damaging the cells. Glycyrrhizin also induced irreversible loss of infec-
tivity of herpes simplex virus type 1.2J [n 1990, Crance et al. investigated forty antiviral 
compounds for their effect on human hepatoma cell line PLCIPRF/5 infected with hepatitis 
A virus. They found a dose dependent inhibition of hepatitis A virus antigen expression and 
reduction of infectivity by glycyrrhizin. At the nontoxic concentrations of 1,000 and 2,000 
J1g/ml, glycYlThizin completely suppressed viral antigen expression.28 Further investigation 
showed that glycyrrhizin did not inactivate the virus nor influenced virus adsorption, but 
it inhibited the penetration of hepatitis A virus. Hepatitis A virus enters cells by receptor 
mediated endocytosis. This process is possibly inhibited by glycyrrhizin by causing a 
decrease of the negative charge on the cell surface and/or by decreasing the membrane 
fluidity. These changes of the cell could prevent penetration of the virus.29 
Cytopmtective effect 
Shiki et al. found that isolated rat hepatocytcs incubated with anti-liver cell membrane 
antibody plus complement release aspartate aminotransferase (AST). This AST release 
was likely to bc caused by lysis of the cell (membrane) afler activation of the membrane 
phospholipase A, by the antigen-antibody reaction. After adding glycyrrhizin to tltis 
system the AST release by the hepatocytes decreased sigttificantly. Further investigation 
suggested that glycyrrhizin inhibited the activation of phospholipase A,.30 
Nakamura et al. induced leakage of lactic dehydrogenase (LDH) and glutamic 
oxaloacetic transaminase (GOT) in a monolayer culnlre of rat hepatocytes by exposing 
these cells to carbon tetrachloride (CCI). This enzyme leakage was caused by a change in 
membrane permeability. The addition of glycyrrhizin caused a dose-dependent reduction 
of enzyme release; it was slightly effective at 25 flg/ml and maximally effective at 200 
flg/m!. Glycyrrhizin probably acted by a direct protective effect 011 the hepatocyte mem-
branes by preventing a change in cell penneability.31 
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In a comparable ill vitro study Nose ef al. compared the hepatoprotective action of 
glycyn'hizin and glycyrrhetinic acid. They found that glycyrrhetinic acid was effective 
in decreasing the transaminases in a concentration of 5 /lg/ml and glycyrrhizin was only 
effective at a dosage of 1000 j.lgiml. This study suggests that glycyrrhetinic acid is a better 
hepatoprotective drug than glycyrrhizin.32 
After ischemia-reperfusion damage of the liver in rat models the serum levels of AST, 
ALT, LDH and lipid peroxides in liver tissue increased, while the liver gluthatione con-
centration decreased significantly. Pretreatment of the rats with subcutaneous glycYlThizin 
for 10 days suppressed the elevation of lipid peroxides and serum AST, ALT and LDH, 
while the glutathione concentration in liver tissue remained at control level. Glycyrrhizin 
suppressed liver damage by acting as a hydroxyl-radical scavenger. Pretreatment 
with glycYlThizin also reduced the morphological damage as assessed by electron 
microscopy. :33, J-t 
111l11111110mod,lla/;oll 
Takahara ef al. found that glycyrrhizin suppressed the secretion of HBsAg and enhanced 
its accumulation dose-dependently in the HBsAg expressing human hepatocellular 
carcinoma cell line PLCIPRFi5, without cytotoxicity. The mechanism of action was 
investigated in cells infected with recombinant varicella vims expressing HBsAg. It was 
found that glycyn'hizin inhibited the sialylation of HBsAg. As desialylated HBsAg has an 
improved inullunogenicity in humoral antibody and cell mediated response, glycyrrhizin 
may improve the immunological status of HBV infected patients by enhancing the 
iml11unogenicity of HBsAg.35 
Cytoplasma 
acts as a radical 
scavenger o 
Hepatocyte 
Possible mechanism of action of glycyrrhizin in the hepatocyte 
Figur.3 
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Introduction 
Abc et al. found that intravenous injection of glycynhizin in mice induced two peaks of 
'Y-intelferon. For this IFN induction T-ceJls and macrophages were required. Intravenous 
injection of glycyrrhetinic acid induced one interferon peak, so inllus model glycyrrhizin 
is superior to glycyrrhetiIuc acid in inducing IFN.36 
In mice, subcutaneously adnurllstered glycyrrhizin selectively activated extrathynuc T cells 
in the liver, without affecting T-cells in the thymus. These activated T-cells were T cells 
with intermediate T-cell receptors, thus double negative CD,' CD; as well as single 
positive CD: or CD;; and may have cytotoxic activity against virally infected cells." 
Clinical investigations 
The first double blind placebo controlled randomized study in cln'onic hepatitis patients 
was published in 1977 by Suzuki et al. in Japanese,' and in 1983 in English·\8 In tlus study 
glycyrThizin was given as Stronger Neo-Minophagen C (SNMC). Tlus is a solution for 
intravenous use consisting of 2 mg glycyrrhizin, I mg cysteine and 20 mg glycine per 
ml in physiological saline solution. Glycine was added bccause it is supposed to prevent 
pseudoaldosteronism and cysteine should be detoxificative through cystine-conjugation 
in the liver. During 4 weeks 40 ml SNMC (= 80 mg glycyrrluzin) was given daily to 
67 patients with lustologically documented cln'onic hepatitis; 66 comparable patients 
received a placebo SNMC containing O.lmg/ml glycyrrhizin (= 4 mg glycyrrhizin daily). 
During treatment, a significant improvement in serum transaminases occurred in the 
SNMC treated patients compared to the placcbo group. No marked side effects were 
observed; after discontinuation of the SNMC, the transallunase reboullced. Step-wise 
witbdrawal therapy after eight weeks treatment with a daily dose of 100 ml SNMC 
resulted in less rebound of transaminases.39 
Hino e1 al. found that 100 ml SNMC daily for 8 weeks not only improved the serum 
transaminases but also the pathological features of a liver biopsy as compared to the 
biopsy before treatment. Thirty-nine patients with chronic hepatitis were treated with 
SNMC, the control group consisted of 54 comparable patients. During alld until 8 weeks 
after SNMC treatment the transaminases decreased significantly; in the control group no 
change occun·ed. The pathological diagnosis in the SNMC treated group improved in 
44%, remained unchanged in 53% and worsened in 3%. No information is given about the 
histological changes in the control group.' 
Xianshi et al. showed that oral administration of glycyrrhizin can significantly improve 
liver function. In tlus study 7.5 mg glycyrrhizin in a capsule had been given orally twice 
a day for 30 days for acute hepatitis and for 90 days for chronic hepatitis. Seroconversion 
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from HBeAg positive to HBeAg negative occurred in 15% and from HBsAg positive to 
HBsAg negative in 25% of the glycyrrhizin treated patients whilc no seroconversion 
occurred in the control group. No side-effects are mentioncd.40 
In Europe, experience with SNMC for the treatment of chronic hepatitis has been 
restricted to Germany. After 12 years experience Wildhirt concluded that the biochemi-
cal and histological improvements after SNMC were larger than those obtained after 
interferon, which is more expensive and has more side effects. The antiviral effect of 
SNMC was comparable to that of intelferon. These conclusions came from open uncon-
trolled studics with patients that did not respond to previous medication" 
A retrospective study, performed by Amse el al., suggests that long-term usage of 
SNMC is effective in preventing HCC development in patients with chronic hepatitis C. 
Eighty-four patients without cirrhosis treated with 100 Illl SNMC daily for 8 weeks and 
2 - 7 times a weck for 2 - 16 years (median 10.1 years) wcre compared to 109 patients not 
treated with SNMC because there was no home health care professional available to give 
the intravenous injections. HeV was diagnosed in stored serum by second generation anti-
HCY tests. The diagnosis of HCC was made by the typical hypervascular chanlcteristics 
observed 011 angiography. The cumulative HCC appearance rate in the SNMC and control 
group were 7% and 12% respectively after 10 years, and 12% and 25%, respectively after 
15 years. In the SNMC group ALT levels became normal in 30 of 84 patients (35.7%) 
compared to 7 of 109 patients (6.4%)in the control. In patients with ALT normalization 
the appearance of hepatocellular carcinoma was rare. Discontinuation because of side 
effecls did not occur." 
Discussion 
In Japan glycyrrhizin has been accepted as a treatment for chronic hepatitis for more 
than 20 years. Nowadays slightly less than 100 million ampoules a year with 40 mg of 
glycyrrhizin are produced in Japan for the treatment of chronic hepatitis. 
Suzuki showed in a double blind randomized controlled trial that in patients with 
chronic hepatitis (not specified) the seml11 transaminases decreased during the treatment 
with intravenous glycyrrhizin given as SNMC. After discontinuation of the medication 
the serum transaminases rebounced, but tIus could be prevented by low dose maintenance 
therapy. In this respect glycynhizin resembles ribavirin." As found by Arase el al.," 
long-term usage of intravenous glycyrrluzin, or to be precise SNMC, appears effective in 
reducing the complications (hepatocellular carcinoma) of c1n'onic hcpatitis C. Contrary to 
IFN therapy, SNMC-treatment showed hardly any side-effects. These two studies suggest 
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that the long-term use of SNMC is safe and effective for non-responders after interferon 
therapy, in reducing the rate of HCV progression. 
There are many gaps in our knowledge with regard to glycyrrhizin as a treatment 
for chronic viral hepatitis C. III vitro glycyrrhizin has antiviral activity against herpes 
simplex virus and hepatitis A virus. However, it is unlikely that glycyrrhizin induces 
viral clearance in chronic hepatitis C, because directly after cessation of the treatment, 
transaminases rise, indicating that the cause of the inflammation (HCV) is still present. in 
vitro glycyrrhizin is hepatoprotective, probably by preventing changes in cellmembranc 
permeability. The observation that long-term glycyrrhizin treatment reduces HCV 
complications in patients suggests that glycyrrhizin also acts hepatoprotective in humans, 
although the precise mechanism is not known. 
The optimal treatment schedule is not known. In Japan, SNMC is given according to 
the level of transaminases; if the transaminases rise, the dosage and frequency of SNMC-
treatment wiB be increased. 
The studies of Suzuki ef al. 38 and Arase ef alY are petfonned with intravenous 
glycyrrhizin given as SNMC. Is the effect caused by glycyrrhizin or is it the combination 
of glycyrrhizin with glycine and cysteine that causes the effect? And is the intravenous 
way of administration essential to reaeh effectivity or is it possible to give an oral 
glycyrrhizin preparation? Orally administered glycyrrhizin will show up as glycyrrhetinic 
acid after absorption. Therefore it is important to find out whether the hepatoprotective 
effect is caused by glycyrrhizin or glycyrrhetinic acid or both. 
To fill in these gaps it seems logical -on basis of the Japanese experience- to do a 
systematic evaluation of intravenolls and oral glycyrrhizin therapy in controlled clinical 
studies. It will also be very important to elucidate unanswered questions regarding the 
underlying mechanism of action. 
Although the optimal treatment strategy still has to be found, glycyrrhizin is a 
potentially effective dmg in reducing long-term complications in chronic viral hepatitis C 
in patients who do not respond with viral clearance to IFN therapy. 
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Abstract 
Background: In Japan, glycyrrhizin therapy is widely used for cln'onie hepatitis C and 
reportedly reduces progression of Hver disease to hepatocellular carcinoma. The aims of 
this study were to evaluate the effect of glycyrrhizin on serum alanine aminotransferase 
(ALT), hcpatitis C virus (HCY)-RNA and its safety in European patients 
Methods: Fifty-seven patients with cln'Onie hepatitis C, non-rcsponders or unlikely to 
respond (genotype 1 / cin-hosis) to interferon therapy, were randomized to one of the four 
dose groups: 240, 160 or 80 mg glycyrrhizin or placebo (0 mg glycyrrhizin). Medication 
was administered intravenously thrice weekJy for 4 weeks; follow-up also lasted 4 weeks. 
Results: Within 2 days of start of therapy, serum ALT had dropped 15% below baseline in 
the three dosage groups (p<0.02). The mean ALT decrease at the end of active treatment 
was 26%, significantly higher than the placebo-group (6%). A clear dose-response effect 
was not observed (29, 26, 23% ALT decrease for 240, 160 and 80 mg, respectively). 
Normalization of ALT at the end of treatment occulTed in 10% (four of 41). The effect 
on ALT disappeared after cessation of therapy. During treatment, viral clearance was not 
observed: the mean decrease in plasma HeV-RNA after active treatment was 4.1 x I 0 6 
genome equivalents/mL (95% confidence interval: 0 - 8.2x 1 06, p>O.I). No major side-
effects were noted. None of the patients withdrew from the study because of intolerance. 
Conclusions: GlycYlThizin up to 240 mg, thrice weekly, lowers serum ALT during treat-
ment, but has no effect on HCY-RNA levels. The drug appears to be safe and is well 
tolerated. In view of the reported long-term effect, further controlled investigation of the 
Japanese mode of administration (six times weekly) for induction appears of interest. 
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Introduction 
Chronic hepatitis C infection can be associated with progressive liver disease that may 
evolve insidiously to cirrhosis and carries an increased risk of hepatocellular carcinoma.! 
Alpha-interferon monothcrapy leads to hepatitis C vims (HCY)-RNA clearance in a 
minority of patients. Although combination therapy with Ribavirin increases efficacy, the 
sustained response rate is still below 50%.' 
For patients who do not respond with viral clearance, different treatment strategies 
have to be sought. These approaches include virus suppressive or hepatoprotective 
medication. In long-term snldies on chronic hepatitis Band C, persistent normalization 
of alanine aminotransferase (ALT) appears to be a key prognostic factor for reduction of 
complications, regardless of the presence of viral markers in the serum.3-6 
Glycyrrhizin 
Molecular structure of glycyrrhizin 
Figure 1 
HoC COOH 
steroid like Glucuronic acid 
In Japan, glycyrrhizin extracted from the roots of the plant Glycyrrhiza glabra 
(liquorice) has been used for the treatment of chronic hepatitis for more than 20 years.' 
Glycyrrhizin is a conjugate of a molecule of glycyrrhetinic acid and two molecules of 
glucuronic acid (Figure I). Suzuki ef al. found that treatment with glycynhizin, given as 
Stronger Neo-Minophagen C (SNNfC, an aqueous solution for intravenous administration) 
lowered the serum transaminases significantly.s However, after discontinuation of the 
medication, the serum transaminases rebounded. Glycynhizin has no influence on the 
viral load.' Despite this finding, Arase ef al. recently reported that long-term treatment 
with glycynhizin ofJapanese patients with chronic hepatitis C, prevented the development 
of hepatoceHular carcinoma when ALT normalized:'! 
At present millions of ampoules of SNMC, each containing 40 mg glycyrrhizin, are 
used each year in Japan for the treatment of chronic hepatitis. It is remarkable that a 
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drug which is used in Japan and other Asian countries on stich a large scale is virtually 
unknown in Europe and the USA. Can this discrepancy be explained by a difference in 
efficacy of glycyrrhizin between Asian people and Caucasians, for instance due to genetic 
polymorpllisms in drug metabolism? 10 
We performed a randomized, double-blind, placebo-controlled trial to evaluate whcther 
the effect of glycyrrhizin on serum ALT is also demonstrable in European patients. 
Methods 
Patients 
Patients were recruited from the University Hospital Rotterdam between February 1997 
and March 1998. Patients between 18 and 65 years of age were eligible if they met 
all inclusion criteria: scnUll antibodies against HeV; HCV-RNA-positive; SCI11I1l ALT 
at least 1.5-fold the upper limit of normal in the 8 weeks prior to treatment and at 
cntry; liver biopsy consistent with mild to moderate fibrosis or cirrhosis with mild to 
moderately active hepatitis; relapse after, non-response to or unlikely to respond to 
interferon (cirrhosis, genotype I); or contra-indication for or refusal to take interferon. 
Patients were not eligible if they met one or more exclusion criteria: other catlses of 
liver disease: chronic hepatitis B, alcohol abuse, auto-immune hepatitis, hemochroma-
tosis, Wilson's disease, a-I-antitrypsin deficiency; decompensated cinhosis, hepatocel-
lular carcinoma; significant cardiovascular or pulmonary dysfunction in the past 6 
months; maHgnancy in the previous 5 years; human immunodeficiency virus 112 infection; 
immunosuppressive therapy; antiviral treatment in the preceding 3 months; pregnancy, 
breast-feeding; hypokalemia and liquorice addiction. 
The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The Protocol was approved by the Medical Ethical COlmnittee of the Erasmus 
Medical Center Rotterdam and all patients gave their written informed consent. 
Stlldy Design 
Patients were stratified for the presence or absence of cirrhosis and were randomized to 
receive a high (240 mg), a standard (160 mg), a low (80 mg) dose glycynhizin or placebo 
(0 mg glycyrrhizin). Randomization was pelformed by means of a computer-generatcd 
randomization schedule made by the statistician. The randomization code was known to 
the statistician and the Department of Pharmacy where the medication was packaged and 
labeled with consecutive randomization numbers. During the study neither the patients 
nor the physicians were aware of the dose of the trial dl1lg. After completion of the clinical 
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part of the study and closure of data collection, the randomization code was broken and 
the physicians and patients were notified of the actual treatment. 
Glycyrrhizin was given as Stronger Neo-Minophagen C (SNMC), a clear solution for 
intravenous use, consisting of2 mg glycynhizin, Img cysteine and 20 mg glycine per mL 
physiological saline. The placebo consisted of I mg cysteine and 20 mg glycine per mL 
physiological saline. 
Both SNMC and placebo ampoules were supplied by Minophagen Pharmaceutical Co., Ltd., 
Tokyo, Japan. 
Medication per visit consisted of 6 ampoules of20 mL (placebo or verum). The 6 ampoules 
(120 mL) were added to a 250 mL infusion bag containing 100 mL of a 5% glucose solution. 
The time between preparation and administration was less than 4 hours. The 220 mL solution 
was administered intravenously within 15 minutes via an indwelling venous catheter. The 
system was flushed with 25 mL NaCl to ensure administration of all of the medication. 
Because glycyrrhizin has a saponin-like structure it may foam, so that placebo and 
verum ampoules wcrc not fully indistinguishable. After mixing with 100 mL 5% glucose 
both verum and placebo show foaming, so that they became indistinguishable. To keep 
administration double-blind, the infusion bag was prepared by an independent third person. 
Patients were treated as ollt-patients. Medication was administered intravenously thrice 
weekly for 4 weeks (12 infusions). The duration of follow-up after the end of treatment 
was also 4 weeks. Routine hematological and biochemical assessments were performed 
weekly during the treatment pcriod and every 2 weeks during follow-up. Virological asses-
sments were performed on day 0 and day 28 (pretreatment and post-treatment). 
Side effects wcrc checked every visit by asking: "Have you had any (other) medical 
problem since your last visit?". Blood pressure and weight were checked every visit; 
a complete physical examination was carried out before treatment, at the end of treat-
ment and at the end of follow-up. Electrolytes (Na and K) were assessed weekly during 
treatment and every two weeks during follow-up period. 
Because administration took place in a hospital, patient compliance could be noted 
accurately by checking scheduled visits. 
\lilv/ogica/ assessments 
Antibodies to hepatitis C vims wcre determined by screening for antibodies by third 
generation ELISA (IMX, Abbott, Chicago, IL, USA.). 
EOTA-samples taken for HCV-RNA determination were processed into plasma within 
2 h and stored at _700 C. Hepatitis C virus-RNA was determined qualitatively by a 
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modified version of the Amplicor HCV assay (Roche Molecular Systems, Alameda, CA, 
USA); the extracted RNA was resuspended in ISO fll instead of I mL. The level of 
HCY-RNA was assessed quantitatively by means of the branched DNA assay (Quantiplex 
2.0, Chiron Corporation, Emeryville, CA, U.S.A.), which has a lower detection limit of 
200,000 HCY genome equivalents per mL. 
For genotyping, the polymerase chain reaction product generated with the Amplicor 
Hev assay was used. Sequence analysis was performed on an automated sequencer 
(Perkin Elmer, Nieuwerkerk, The Netherlands). The genotype was determined according 
to the rules described by the International HCY Collaborative Study Group. II 
Assessments of outcome 
The primary (biochemical) response parameters were the percentage decrease in ALT 
from baseline and the number of patients with ALT normalization at the end of treatment 
and at the end of follow-up. The secondaty response parameter lVas the virological 
response, defined as the decrease in plasma HCY-RNA. Tolerability and occurrence of 
side-effects were the third outcome measures. 
Statistical analysis 
Before the beginning of the study, a power analysis was performed to determine the size 
of the study population. A linear relationship between the decrease in ALT and dose lVas 
assumed. The analysis was based on a two-tailed comparison with an a of 0.05 and a 
power of 0.80 (P = 0.20). It lVas calculated that to detect a correlation of r = DAD or more 
at least 12 patients were required per dosage group. 
The baseline ALT lVas calculated as the mean ALT level at screening (in the 8 weeks before 
start of the study) and the ALT level on day O. Statistical analysis was performed by using 
Stata 5.0 software (Stata Corporation, College Station, TX, USA). Comparisons between the 
four groups were evaluated using the Kl1Iskal-Wallis test; ifp<0.05 the Mann-Whitney U-test 
was used to perform further comparisons between the groups. Changes within groups were 
assessed with the signed-rank test. Fisher's exact test was applied to compare percentages. 
Results 
Characteristics of patients 
Figure 2 shows the trial-profile. There were 77 potential participants, 13 patients were 
not willing to participate and 7 were not eligible. Therefore 57 patients were randomized 
to receive treatment. One patient dropped-ollt because of social problems. Two patients 
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Clinical trails 
77 total potential participants 
-7 notellgible: ALT < 1.5x ULN 
-13 did not want to participate 
57 patients randomized I 
placebo 80 mg I 160 mg 
" 
240 mg 
n = 14 n = 13 n = 15 n::: 15 
1 not eligible 1 drop out I 11 not eligible 
n -13 n 13 n = 14 n::: 14 
completed completed completed completed 
treatment treatment treatment treatment 
per protocol per protocol per protocol per protocol 
were mistakenly randomized: one patient had a normal ALT value on day 0; the other 
had several protocol violations: ALT on day 0 was 1.3 x upper limit of normal, liver 
biopsy showed no fibrosis and the time between antiviral (intelferon) treatment and start 
of the glycyrrhizin study was less than 3 months. These two patients were included in 
the safety and tolerability analyses. Statistical analysis of all randomized patients led to 
the same conclusion as analysis of the 54 patients who completed treatment according 
to protocol; the efficacy data on 54 patients and the safety data on 56 patients are 
presented. 
The baseline characteristics of the 54 paticnts are shown in Table I. The groups appear 
well-balanced. Each group consisted of approximately 40% patients with liver cirrhosis. 
Most patients were Caucasian. About 80% of the patients per group were male. Although 
the average baseline level of ALT in the 240 mg group was lower than in the other groups, 
there was no significant difference between the four groups (Kruskal-Wallis p=0.13). 
Median HCY-RNA levels were ffi'Ound 107 gcnome equivalents per mL. 
Biochemical Respollse 
Figure 3 shows the effects of the placebo and the three doses of glycyrrhizin on the ALT 
level during the study. Within none of the four groups there was a significant difference 
between ALT at screening (in the 8 weeks before start) and ALT on day 0 (p>0.09). 
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Table I 
General characteristics of the 54 patients analyzed for efficacy at baseline per group. 
Group Omg 80mg 160mg 240mg 
number 13 13 14 14 
ca ucasian/black/other 8/0/5 8/0/5 5/2/6 10/0/4 
male/female 13/0 11/2 10/4 11/3 
age median (range) 47 (37~60) 45 (32~66) 52 (35~69) 44 (3Hl) 
non cirrhosis/cirrhosis 7/6 8/5 8/6 8/6 
previous interferon yes/no 1211 10/3 11/3 11/3 
All baseline (x UlN) median (range) 3.1(1.5~6.8) 3.4(1.4~11.8) 3.0(1.8~6.9) 2.2(1.6~5.2) 
y~GlP (x UlN) baseline median (range) 1.9(0.5~ 10.0) 1.4(0.4~10.4) 2.1(0.7~8.1) 1.2(0.4~3.7) 
H(V~RNA x10' genome eq/ml,median (range) 4.5(1.4~39.2) 21.7(0.2~ 104) 11.1(1.H6.9) 14.4(1.1~51.4) 
genotype la/1b/2/3/4a 1/6/1/3/2 3/3/2/5/0 2/6/4/1/1 214/2/6/0 
ALT= alanine aminotrans(erase;y-GTP= gamma glulamyltranspeptidase.ALT and ,,(-GTP baselines were calculated as the mean value at 
screening (in the 8 weeks before start) and at day O. UlN= upper limit of normal 
2 
~;=-----. ~J; ~ __________ ~* 
~~ 
• • ~ •. p~cebo 
.". 80 mg 
~16Omg 
SNMC 3 x week intravenously '.' 240 mg 
O~~------,-----~------,---~~~ 
s 0 14 28 42 56 
time (days) 
Median ALT expressed as times the upperlimi! of normal (UlN) according to dosage group . 
• significantiylowerthan baseline (p<O.OS,signed rank test) I Significantly higher than All at the end of treatment (day 281 (p<O.OS,signed rank test) 
Figure 3 
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During the study period there was no significant change in ALT in the placebo group. 
Within 2 days of start of therapy serum ALT dropped 15% below baseline in the three 
dosage groups (p<0.02) and remained significantly lower, except in the 80 mg group on 
day 28. 
During follow-up after the end of treatment ALT levels tended to increase again; only in 
the 240 mg group were ALT levels at the end of foHow-up significantly higher than at the 
end of treatment (p=0.02). At the end of follow-up the ALT values in the 80 and 240 mg 
groups were significantly lower than the baseline value (p<O.OI and 0.05, respectively). 
ID 15 0> 
C 
'" £ 0 
'=' 
0-
=F « <f. 
-15 
-30 iT 
45 
-eo 
placebo 80 mg 'ffimg 240 mg 
Mean percentage change in ALT at the end of treatment with respect to baseline ± 95% confidence interval per dosage group. 
* significantly greater than placebo group (p<O.Ol,ranksum test) 
Figur.4 
During treatment it was found that on all assessment days the percentage decrease in 
ALT was significantly higher in the treatment groups compared to the placebo group (all 
p<O.03), while there was no difference between the three activc groups. Figure 4 shows 
the mean percentage ALT decrease from baseline at the end of treatment per group. The 
mean percentage decrcase for thc three glycyrrhizin groups at that time lVas 23, 26 and 
29 percent, respectively, all being significantly larger than the 6% decrcase found for the 
placebo group. 
The percentage patients exhibiting ALT normalization at the end of treatment was 
o (0/13), IS (2/13), 0 (0114) and 14 (2114) in the 0, 80, 160 and 240 mg glycyrrhizin 
groups, respectively. Only I patient in the 240 mg group had a normal ALT at the end of 
follow-up. There was no significant differcnce in ALT normalization between the 4 groups 
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at the end of treatment and at the end of foHow-up. There was no significant difference 
in y-glutamyUranspeptidase (y-GTP) at baseline and y-GTP at the end of treatment (all 
p>0.08) within any of the four groups (Figure 5). 
3 2.5 
::> 
~ 2 n 
1.5 • 
• 
placebo 
0.5 
~ 80mg 
~ 160mg 
~ 240 mg SNMC 3 x week intravenously O~~~-----,------~------,-----~~~ 
o 14 28 
Ii"" (days) 
Median 'Y-GTP expressed as times upper limit of normal (UlNJ according to dosage group. 
Figure 5 
Virological Response 
42 56 
The HCY-RNA levels at baseline were high (range of 0.2 - I 04x I 06 genome equivalents 
per mL) as a result of selection of the patients (the majority were non-responders to 
interferon). After treatment HCY-RNA was still detectable in all patients. In each of the 
four groups the HCY-RNA levels at the end of treatment did not differ significantly from 
those at baseline (all 1'>0.1 I; Table II). The mean change in plasma HCY-RNA after 
active treatment was -3.1xl06 genome equivalents/mL (95% confidence interval: -6.2, 
-0.lxI06). 
Safety and Tolerability 
The expected side-effects of glycyrrhizin are: hypokalemia, sodium retention, increase in 
body weight, elevated blood pressure and retention of body fluids (i.e. edema). 12 None of 
these expected side-effects were observed during the study. 
Table III shows the adverse events mentioned by more than 2 patients in the course of 
the study spontaneously or after the question: "Have you had any (other) medical problem 
since your last visit?". 
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Table II 
Median HCV-RtlA levels before and al the end oftreillment and mean HCV-RNA (hange per groupJigures ill parentheses represent the range of data. 
Glycyrrhizin Irealm.nl 
HCV·RNA (10' geqlmL) Omg 80mg 160mg 240mg 
Before treatment 4.5 (1.4·39.2) 21.7 (0.2·104) 11.1 (1.4·66.9) 14.4(1.1·51.4) 
At the .nd of treatm.nt 6.9 (1.4·38.3) 17.8 (0.5·73.2) 11.5 (1.9·61.6) 8.9 (4.4·43.8) 
Mean (hang' ·0.3 (·4.3,5.0) ·3.6(·30.8,13.3) ·1.6 (-27.7, 17) -7.3 (·42.3,12.1) 
HCV=hepatitis ( virus;geq=genome equivalents. 
Tabl.1II 
Number of patients, who mentioned an adverse event spontaneously or after the question: "Have you had any (other) medical problem 
since your last visit?" Fifty-six patients were analysed, 
Glycyrrhizin lrealm.nl (mg) 
Adv.rs. Evenl \ Group o (n=14) 80 (n=13) 160(n=14) 240(n=15) Tolal p-value a 
Headache 5 2 1 5 13 0.21 
Having a {old ["flu like"symptoms 0 6' 3 10 0.01 
Increased fatigue since treatment 2 2 3 8 0.73 
Pain/haematoma at puncture site 3 6 0.67 
Strange feeling during administration 2 2 0 5 0.48 
Diarrhea 0 3 5 0.35 
Stitches in region of liver 0 3 1.00 
Rash/itching 0 0 1 2 3 0.61 
Dizziness 0 3 0.89 
Nausea 0 3 0.89 
Total with at least one side effect 10 10 13 10 43 0.63 
a over-all p-value determined by using Fisher's exact test. b significantly higher than placebo (p= 0.016 Fisher's exact test). 
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Headache, increased fatigue since treatment, pain or hematoma at the puncture site, 
strange feeling during administration, stabs of pain in the region of the liver and dizziness 
were mentioned by patients of the placebo as well as the 3 dosage groups. No significant 
differences between the foul' groups were observed. Cold or "flu-like" symptoms, diarrhea, 
rash or itching and nausea were not mentioned by patients of the placebo group, only by 
patients of one of the thrce dosage groups. The only statistically significant difference was 
six patients of the 160 mg group with cold or "flu-like" symptoms; this was significantly 
higher than the 0 patients of the placebo group (Fisher's exact test, p~0.0l6). The number 
of patients reporting an adverse event did not differ significantly between the four groups 
(Fisher's exact test, p~0.63). 
Treatment was generally well tolerated, no patients were lost due to intolerance. 
DisclIssion 
This European phase IIII study confirms the effect of glycyrrhizin in lowering serum ALT, 
as already observed in Japan. The efficacy of glycynhizin in normalizing serum ALT in our 
study was less than that reported in Japan. In our study 10% (4/41) of the patients treated 
with glycyrrhizin achieved ALT levels within the normal range at the end of treatment, 
while in Japan 36% of the patients exhibited this important outcome measure.'1l is possible 
that Asian people benefit more from glycyrrhizin treatment dne to genetic polymorphisms 
in drug metabolism. Another possible explanation might be the difference in treatment 
schedules. In Japan, daily administration of glycyrrhizin is standard practice. In Europe, 
however, it is unusual to treat patients daily with intravenous medication, for which they 
have to visit the hospital. Therefore in our study glycyrrhizin was administered three times 
a week. We expected at least a 15% drop-out rate because of intolerance. However, we did 
not have any dropouts due to intravenous drug administration. In view of our observation 
that the thdce weekly schedule lVas well tolerated, it seems logical to conduct an additional 
study in which European patients are treatcd according to the Japanese schedule to find out 
whether the different treatment schedule was the cause of the difference in efficacy. 
Treatment with SNMC rapidly induces a significant decrease in ALT. Within the four 
groups there was no significant difference between ALT at screening and ALT on day 0, 
but within 2 days of the first dose of glycyrrhizin ALT became significantly lower than 
baseline (p<0.02 signed rank test), while no such effect was seen in the placebo group. 
We may therefore conclude that the observed ALT decrease during active treatment is not 
caused by a nanlfal fluctuation of ALT in chronic hepatitis C patients. After cessation of 
therapy the ALT-decreasing effect of glycyrrhizin disappeared. 
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The mechanism by which glycynhizin decreases the transaminases is not known. One 
of the proposed mechanisms is that glycynhizin induces ALT decrease by stabilizing the 
cell membrane of the hepatocyte." 
In the present study glycyrrhizin was given as SNMC, which contains glycyrrhizin and 
a ten-fold higher concentration of glycine. Both molecules are said to be hepatoprotective 
ill villV."'" The placebo used in this trial consisted of all the ingredients of SNMC except 
for glycyrrhizin. Because the serum ALT did not drop in the placebo group, whereas it 
was decreased significantly in the !luee SNMC groups, we can conclude that the ALT-
decreasing effect of SNMC in this study is caused by glycyn'hizin and not by glycine. 
None of the 57 randomized patients left the study because of drug intolerance. Pseudo-
aldosteronism, with sodiulll retention, hypokalemia and hypertension, is a well known side-
effect of glycYlThizin." This phenomenon is caused by the metabolite glycyn'hetinic acid, 
which inhibits the conversion of cortisol to cortisone by the enzyme II ~-hydroxy-steroid­
dehydrogenase in the kidney. Tlus inIubition leads to increased cortisol levels in the kidney. 
Because cortisol and aldosterone bind with the same affinity to the mineralocorticoid receptor, 
a rise in renal cortisol will result in a hypermineralocorticoid effect. ls In our study we did not 
observe sodium retention, hypokalemia, hypertension or an increase in body weight. Possibly 
the addition of glycine prevented the OCClllTence of these side-effects, as reported by Suzuki el 
al.s Alternatively, the adnunistered dose of glycyrrhizin -a maximum of 720 mg glycyrrhizin 
per week (103 mg/day)- is too low to cause side-effects. Side-effects are more likely to occur 
when the daily dose of glycyrrhizin is several times more than 103 mg. l6 
Unexpected side-effects as headache, increased fatigue since treatment, a strange 
feeling during administration and pain or hematoma at the puncture site were encountered 
as often in the placebo group as in the glycyrrhizin groups; so these symptoms are -in all 
likelihood- not caused by glycyrrhizin itself but by the total treatmcnt (e.g., visiting the 
hospital three times a week; receiving intravenous medication). Therefore treatment with 
SNMC up to 240 mg, thrice weekly for 4 weeks, appears to be safe and well tolerated. 
In conclusion, we confirmed that a minority of the European patients normalized ALT 
during glycyrrhizin therapy. 
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Abstract 
BackglVlmd: In Japan, ALT-normalization induced by long-term intravenous glycynhizin 
treatment reportedly reduces the progression of liver disease to hepatocellular carcinoma 
in chronic hepatitis C patients. 
Aims: To evaluate the short-term (4 wecks) feasibility and efficacy on senlm ALT of 3 or 
6 times per week intravenolls glycyrrhizin therapy in European patients. 
Methods: Patients with chronic hepatitis C, non-responders or unlikely to respond 
(genotype 11 cirrhosis) to interferon therapy, were included in tltis study. Medication was 
administered intravenously 3 or 6 times per week for 4 weeks; follow-up also lasted 4 
weeks. 
Results: Sixty-nine patients completed the treatment according to protocol. There were no 
significant changes in ALT-Ievels within the placebo group (n=13). The mean percentage 
ALT decrease from baseline at the end of treatment was 26% and 47% for the three times 
per week and six times pcr week treatment group, respectively (both P<O.OO I versus 
placebo). At the end of active treatment 10% (4/41) and 20% (3/15) of the patients 
reached normal ALT levels for the three times per week and six times per week treatment 
group, respectively. The ALT lowering effect disappeared after cessation of treatment. No 
major side effects were observed. 
Conclusions: It appeared feasible to treat European outpatients with chronic hepatitis C 
3 or 6 tinlCS per week with intravenous glycyrrhizin. Glycyrrhizin treatment induces a 
significant ALT decrease in patients with chronic hepatitis C. Six times a week treatment 
appears more effective than 3 times a week. 
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Introduction 
Treatment of chronic hepatitis C infection with alpha interferon and ribavirin combination 
therapy results in a sustained virological response in less than 50% of the treated patients. [-3 
For those who do not respond with viral clearance, different treatment strategies have to 
be sought. In long-term studies on chronic hepatitis Band C, persistcnt normalization of 
alanine aminotransferase (ALT) appears to be a key prognostic factor for reduction of long-
term complications, regardless of the presence of viralmarkcrs in the serum.4-S 
In Japan, glycyrrhizin - cxtracted from the roots of the plant Glyc)'l"Illiza glabra (liquoricc)-
has been used for the treatment of chronic hepatitis for more than 20 years.9 Glycyrrhizin is 
a conjugate of a molecule of glycyrrhctinic acid and two molecules of glucuronic acid. 
In 1997 Arase e/ al. reportcd that in Japanese patients with chronic hepatitis C, long-tenn 
treatment (median 10.1 years) with 2-7 times per week intravenous glycYIThizin, prevented 
the development of hepatocellular carcinoma when ALT normalized.' Ito reported that 
glycyrrhizin treatment does not influence the viral load. 10 
At present nearly 100 million of ampoules of SNMC - each containing 40 mg glycyrrhizin -
are used each year in Japan for the treatment of chronic hepatitis. It is remarkable that a drug, 
which is used in Japan and othcr Asian countries on stich a large scale, is virtually unknown 
in Europe. In Europe it is unusual to treat patients with daily intravenous medication in 
the outpatient clinic. Therefore the feasibility and the efficacy of glycyrrhizin treatment 
in European patients should be evaluated. We performed a double-blind, randomized, 
placebo-controlled study in which medication was administered 3 times a week. II In 
this study only ten percent of our patients treated with glycyrrhizin reachcd a normal 
ALT-value at the cnd of treatment, while in Japan 36% of the patients reached ALT 
normalization albeit with daily administration.5 To evaluate whether we could increase the 
efficacy and whether it is feasible in Europe to administer 6 x week i.v. medication we 
extendcd the study with a second part in which glycyrrhizin was given 6 times a week. 
Here we report the combined results of the two treatment modalities for intravenolls 
glycyrrhizin in a European setting. 
Material & methods 
Patients 
Patients between 18 and 70 years of age were eligible if they met all inclusion criteria: serum 
antibodies against HCV, HCV-RNA-positive; serum alanine aminotransferase at least 1.5 times 
the upper limit of normal (ULN) in the 8 weeks prior to treatment and at start of treatment; 
liver biopsy consistent with mild to moderate fibrosis or cirrhosis with mild to moderately 
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active hepatitis; relapse after, non-response to or unlikely to respond to interferon based therapy 
(cirrhosis, genotype 1); or contra-indication for or refusal to take interferon based therapy_ 
Patients were not eligible if they met one or more exclusion criteria: other causes of liver 
disease: chronic hepatitis B, alcohol abuse, auto-immune hepatitis, hemochromatosis, Wilson's 
disease, alpha-I-antitrypsin deficiency; decompensated cilThosis, hepatocellular carcinoma; 
significant cardiovascular or pulmonary dysfunction in the past 6 months; malignancy in 
the previous 5 years; HIV infection; imlllunosuppressive therapy; antiviral treatment in the 
preceding 3 months; pregnancy, breast-feeding; hypokalemia and liquorice addiction. 
The studies were conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The Medical Ethical Committee of the Erasmus Medical Center Rotterdam 
approved both protocols and all patients gave their written informed consent. 
Study Design 
Glycyrrhizin was given as Stronger Neo-Minophagen C (SNMC,Minophagen Pharmaceutical 
Co., Ltd., Tokyo, Japan.), a cIear solution for intravenous use, containing 2mg glycyrrhizin, 
1 mg cysteine and 20 mg glycine per ml in saline. 
Part I (double-blind, randomized, placebo-controlled trial): placebo (SNMC without 
glycYlThizin) or glycyrrhizin (80, 160 or 240 mg) was given intravenously 3 times a week. 
Medication was diluted with 100 nu glucose 5% and administered by drip infusion in 
15-20 minutes. 
Part II (open study): 200 mg glycyrrhizin (100 nu SNMC) was administered six times 
per week. Undiluted medication was directly injected into a peripheral vein via a butterfly 
needle (Neofly® 21 G Ohmeda, Japan) in 3-5 minutes. Eight of the 15 patients in tllis study 
received placebo and 5 of the 15 received active treatment in part I; the time between the 
two treatments was at least 6 months. 
Treatment duration for both pm-ts was 4 weeks; follow-up thereafter was also 4 weeks. 
Routine hematological and biochemical assessments were performed weekly during the 
treatment period and every 2 weeks during follow-up. Virological assessments were 
performed on day 0 and day 28 (pre-treatment and at the end of treatment). Side effects 
were checked every visit by asking: "Have you had any (other) medical problem since 
your last visit?". Patients were treated as outpatients. Because administration took place 
in a hospital, patient compliance was directly linked with scheduled visits. 
Virological assessments 
Anti-HCV was determined by third generation ELISA (IMX, Abbott, Chicago, IL, USA.). 
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EDTA-blood samples were centrifuged within two hours, plasma was stored at -70' C. 
HCV-RNA was determined qualitatively by a modified version oftheAmplicor HCV assay 
(Roche Molecular Systems, Alameda, CA, USA); the extracted RNA was re-suspended 
in 150 pi instead of 1 Ill!. HCV-RNA was quantified by means of the branched DNA 
assay (Quantiplex 2.0, Chiron Corporation, Emeryville, CA, U.S.A.), which has a lower 
detection limit of 200,000 HCV genome equivalents per ml. 
For genotyping, the peR product generated with the Amplicor HCV assay was used. 
Sequence analysis was performed on an automated sequencer (Perkin Elmer, Nieuwerkerk, 
The Netherlands). The genotype was determined according to the rules described by the 
International HCV Collaborative Study Group.12 
Assessments of olltcome 
The primary (biochemical) response parameters were ALT-nonnalization at the end of 
treatment and the mean percentage decrease of ALT from baseline at the end treatment. 
The secondary response parameter was the virological response, defined as more than 
one lOlog decrease in plasma HCV-RNA. 
Tolerability and side effects were also monitored. 
Statistical analysis 
Statistical analysis was performed by using Stata 5.0 software (Stata C0l1JOration, College 
Station, Texas, USA). The baseline ALT was calculated as the mean of two values: ALT 
levcl at screening (in the 8 weeks before start of the study) and ALT level on day O. A 
linear relationship between the mean decrease in ALT and treatment dose was assumed 
in the power analysis of the randomized part of the study. Tilis analysis, based on a two-
tailed comparison with an alpha of 0.05 and a power of 0.80, showed that to detect a 
correlation of r=0.40 or more at least 12 patients per dosage group were required. 
Changes witllin the group were assessed with the Wilcoxon signcd-rank tcst. Comparisons 
between groups were evaluated with Mann-Whitney's test. Fisher's exact test was applied 
to compare percentages. p=0.05 (two-sided) was considered the limit of significance. 
Results 
Characteristics ojpatiellts 
In total fifty-nine patients were treated in our studies. Thirteen of the 15 patients included 
in part II participated also in part I: 8 received placebo and 5 received active treatment. 
Two patients were found not to have met the inclusion criteria; these two patients 
33 
Chapter 2.2 
Part I 
77 lolal potential participants 
~ 7 nol eligible: Al T < 1.5 x ULN 
- 13 did not want to participate 
I 
57 patients randomized 
T I 
3 x per week placebo 3 x per \'·reek glycyrrhizin 
n" 14 n" 43 
1 not el1gihle 1 not eligible, 1 drop out 
I I 
completed treatment completed treatment 
per prclocol per protocol 
n'" 13 n" 41 
Part I: double-blind, randomized, placebo-controlled trial 
Patient flow chart 
Figure 1 
Part If 
21 tolal potential participants 
~ 1 no! eligible: Al T < 1.5 x UlN 
- 5 did not wanl to participate 
I 
15 patients in open study 
- 8 received placebo in part I 
- 5 received active treatment in part I 
Vlash--{lut period> 6 months 
I 
6 x per \veek glycyrrtJlzin 
n" 15 
I 
oompleled trealment 
per protocol 
n" 15 
Part lI:additional open study 
were included in the safety and tolerability analysis. One patient discontinued after one 
administration due to social circumstance, this patient was excluded from analysis. Figure 
I shows the flow of patients. 
As no significant differences regarding ALT normalization and ALT decrease were 
found between the three groups receiving active treatment three times per week (80 
mg (n=13), 160 mg (n=14), or 240 mg (n=14)), these 41 actively treated patients were 
combined into one group (the three times per week frequency group). 
The baseline characteristics of the patients are shown in table 1. About 80% of the 
patients were male; more than 80% of the patients were interferon or interferon/ribavirin 
non-responders. ALT levels were 2.5-3 times the upper limit of normal (ULN: 31 IUII 
for female and 41 lUll for male). The median HCY-RNA levels were around 10' genome 
equivalents per m1. 
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Baseline characteristics of the 69 patients evaluable for efficacy per group. 
Treatment group Placebo 
number of patients 13 
male/female 13/0 
caucasian/other 8/5 
median age*in years (range) 47(37 - 60) 
nand rrhosis/ d rrhosis 7/6 
previous interferon (ribavirin) yes/no 1211 
median All UlW* (range) 3.1 (1.5-6.8) 
median HCV-RNA Mgeneq#./ml (range) 4.5 (1.4 - 39.2) 
genotype-1/genotype non-1 716 
3 xweek 
41 
3219 
23118 
46 (32 - 69) 
24117 
3219 
2.6(1.4-11.8) 
14.9 (0.2 -104) 
20121 
~at start of treatment H upper limit of norma! # Mega genome equivalent 
Biochemical Response 
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6 xweek 
15 
12/3 
11/4 
49 (39 -70) 
7/8 
13/2 
3.0(1.6-12.5) 
14.1 (0.7 -76.3) 
7/8 
For none of the groups there was a significant difference between ALT at screening and 
ALT at day O. No significant changes were observed during study period in the placebo 
group. 
None of the patients receiving placebo showed ALT normalization at the end of 
treatment, 10% of the patients (4/41) after three times per week and 20% (3/1 S) of the 
patients after six times per week glycyrrhizin trcatment reached normal ALT levels at the 
end of treatment; ALT normalization at the end of treatmcnt was not significantly different 
between the three studied groups (p","d=0.12). Figure 2 shows the distribution of ALT at 
the end of treatment. 
After one week of treatment the mean percentage ALT decrease from baseline was 
21 % and 41 % and at the end of treatment it was 26% and 47%, for the three times 
per week and six times per week treatment group, respectively (Figure 3). The mean 
percentage ALT decrease during active treatment (three times and six times per week) 
was significantly greater compared to placebo at all time points (p<O.OO I). Also the 
differences between both active treatment groups were significant (p<O.002). After 
cessation of active treatment ALT levels increased again; there was no significant 
difference between ALT at the end of follow-up and ALT at baseline for any of the groups. 
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8% 
92% 
placebo 
n = 13 
II1II All normal, 
10% 
27% 
63% 
3x week treatment 
n = 41 
.. ALT > normal and ~ 1.5 times UlN, 
20% 
27% 
53% 
6x week treatment 
n = 15 
• All> 1.5 times UlN 
Distribution of ALI at the end of treatmenLAlT is expressed as upper limit of normal (UlN:male 41 lUlL, female 31IU/l}.Patients were 
treated with 3 times per week intravenous placebo or 3 or 6 times per week with intravenous glycyrrhizin for 4 weeks, Before treatment 
all patients had All levels alleast 1.5 x UlN. 
Figure 2 
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The mean percentages All change from baseline. Vertical bars indicate the standard error of the means. After active treatment the mean 
percentage All decrease was significantly lower compared to placebo (*p<O.OOl, **p<O.OOO1). The mean percentage All decrease at 
the end of treatment from baseline was 26% and 47% for three times and six times per week treatment, respectively. Six times per week 
treatment caused a larger decrease than three times per week (#p<O.002). 
figure 3 
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Virological Respollse 
The HeV-RNA levels at baseline were high: range 0.2 - 104xlO' genome equivalents per 
m!. HeV-RNA levels at the end of treatment did not differ significantly from those at 
baseline. None of the paticnts cleared HeV-RNA. 
Safety alld Tolerability 
Expected side effects of intravenous glycyrrhizin treatmcnt are haematoma at the injection 
place and pseudo-aldosteronism with: hypokalemia, sodium retention, elevated blood 
pressure and rctention of body fluids. 13. 14 Only within the six tinles a week treatment group 
minor reversible symptoms of pseudo-aldosteronism occulTcd; the mean serum potassium 
decreased from 4.2±0.3 before treatment to 4.0±0.3 at the end of treatment (1'=0.05) and 
thc mean systolic blood pressure rose from J32±15 to 142±14 (1'=0.01). There lVas no 
significant difference between cirrhotic and non-cirrhotic paticnts with regard to decrease 
of potassium or rise of systolic blood pressure during glycYIThizin treatment. Ten patients 
suffered hacmatoma at the injection place. Hcadache, common cold, more tired than before 
treatment and strange feeling during administration of the mcdication were unexpected 
adverse events mentioned spontaneously by more than 5 patients (Table II). There were no 
clinically significant differences between the three frequency groups. 
Tablett 
Number of patients who mentioned an adverse event spontaneously or after the question:"Have you had any (other) medical problem 
since your last visitr 
Adverse event/frequency group 
Headache 
Common (old 
Haematoma at injection place 
Strange feeling during administration 
More tired than before treatment 
* overall p value (Fisher's exact test) 
significantly lowerthan placebo (p=O.01) 
Oxwe.k 
(11=14) 
5 
0 
2 
2 
b significantly higher than three times per week group (p=O.03) 
3 xweek 
(11=42) 
8 
10 
5 
3 
6 
6xw •• k 
(11=15) total p* 
0' II 0.03 
3 II 0.1 
4 10 0.4 
5' 10 0.04 
0 8 0.3 
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Discussion 
The problem with most herbal remedies is, that there arc no well conducted clinical trials 
in which their efficacy has been evaluated. During the congress "Complementary and 
Alternative Medicine in Chronic Liver Disease (NllI, Bethesda, Maryland, USA, August 
1999) the need for such well conducted trials was stressed. Therefore we pelformed this 
study, according to Good Clinical Practice, in order to evaluate the short-term efficacy 
of glycyrrhizin treatment on senlIn ALT levels and the feasibility of 3-6 times per week 
intravenous glycyrrhizin administration in a European setting. 
Clinically significant adverse events did not occur morc often in the six times per 
week group compared to 3 times per week or placebo; none of the patients left the 
study because of treatment intolerance. So short-term treatment with 3-6 times per week 
intravenous glycyrrhizin appeared feasible and safe for patients with chronic hepatitis C 
or compensated cirrhosis. 
We did not objectivate the quality of life of patients in this short-term study. Most 
patients were interferon nom'cspondcrs, so they were well aware of the benefits of 
seltinjection and the side effects of interferon treatment. However, a number of patients 
requested for longer treatment with glycynhizin instead of maintenance therapy with 
interferon, because they felt better during glycyrrhizin therapy. Therefore the quality of 
life during long-term glycYlThizin treatment should be evaluated. 
Five patients participating in part II received active treatment in part I. It is likely that 
patients who respond well to the treatment are willing to receive another treatment, while 
patients who did not respond are not willing to receive another treatment. The occunence 
of this bias appears unlikely in our study because none of these 5 reached normal ALT 
levels during part I, while the mean percentage ALT decrease of these 5 was only 13%, in 
this part of the study. 
The proportion of patients with ALT normalization at the end of treatment was higher 
in actively treated patients than in placebo, and higher in six times per week than three 
times per week glycyrrhizin administration; but the differences failed to reach statistical 
significance. However, due to the small numbers studied, real differences cannot be 
excluded. Comparing our data with the results reported by Arase ef al./' outcomes 
differed significantly between our placebo versus Arase's data (0% (0/13) vs. 36% (30/84), 
1'=0.008) and our three times per week versus Arase's data (10% (4/41) vs. 36% (30/84), 
1'=0.002), while no significant difference was found between our six times per week 
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versus Arase's data (20% (3/15) vs. 36% (30/84) p=O.4). This confirms that six times per 
week glycyrrhizin administration is more effective than three times per week or placebo. 
The mean percentage ALT decrease at the end of treatment after 6 times per week 
treatment was significantly greater than after 3 times per week treatment (47% (95% CI: 
38-57) vs. 26% (95% Cl: 18-34) p=0.002). Within the three times per week treatment 
group the mean percentage ALT decrease did not show a linear dose response relationship, 
the mean percentage ALT was 23% (95% Cl: 2-43), 26% (23-38) and 29% (21-38) after 
80, 160 and 240 mg glycyrrhizin respectively. This suggests that not only a total week 
dosage of 1200 mg glycynhizin but also six times per week administration are necessary 
to reach a mean percentage ALT decrease of 47%. This hypothesis is corroborated 
by the half-life of glycyrrhizin, which is 8 hours in patients with chronic hepatitis C; 
administration of the medication every 24 hours results in a continuously detectable level 
of glycyrrhizin, wlule with 3 times per week glycyrrhizin adnunistration, glycyrrluzin is 
not detectable anymore after 48 hours. (5 
Is treatment with glycynhizin only beneficial when ALT normalization occurs? Tarao et 
al. recently reported that persistently lugh ALT levels (>80 lUlL) in patients with chronic 
hepatitis C were associated with a more rapid development of hepatocellular carcinoma 
(HCC) than persistently low ALT levels (<80 lUlL). They followed 69 consecutive HCV 
patients with citThosis for more than 5 years; the 5-year rate incidence of HCC was 53.6% 
versus 7.1 %, for the high ALT and low ALT group, respectively. 16 Therefore there is some 
evidence that not only patients with ALT normalization hut also patients with an ALT 
decrease to below 80 lUlL might benefit from long-term glycyrrluzin treatment. 
To confirm the efficacy of glycyrrluzin treatment with regard to the retardation of the 
progression of liver disease, a prospective long-term treatment trial in Europe should be 
performed. If tlus long-term study shows histological improvement, glycyrrluzin can be 
an important treatment in order to reduce the progression of the disease for patients who 
do not clear the hepatitis C virus. 
Wc observed that the decrease of ALT, induced by glycyrrhizin treatment, occurs witlun 
the first two weeks of treatment, thereafter ALT levels remain stable. This is in agreement 
with the finding of Tsubota e1 al. that ALT levels did not significantly change during 3 
times per week 200 mg glycyrrluzin therapy from 4-24 weeks." Based on our current 
results and experience we suggest to start with an induction period in which glycyrrhizin 
is given 6 times per week for at least two weeks followed by a maintenance regimen 
with 3 times a week glycyrrhizin adnulustration. The development of an oral form of 
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glycyrrhizin for maintenance therapy would be a more convenient option for long-term 
treatment. 
The mechanism by which glycyrrhizin reduces the progression of liver disease without 
clearing the virus is unknown. A few in vitro and animal (rat) studies suggest that 
glycyrrhizin or its metabolite glycyrrhetinic acid inhibits lipid peroxidation, thereby 
protecting the hepatocytes. 18." Shiota el al. recently reported the first animal model in 
which they described that treatment with glycyrrhizin significantly reduced the occurrence 
of hepatocellular carcinoma in diethyillitrosamine treated miceY The mechanism in this 
mouse-model is still unclear, but this model might help to unravel a possible mechanism 
of action. 
In conclusion, it is feasible to treat European patients with 3-6 times per week 
intravenous glycYlThizin for 4 weeks. Glycynhizin treatment induces a significant ALT 
decrease in patients with clUOllic hepatitis C. Six tinles per week treatment is more 
effective than three times per week treatment. To evaluate the benefit of treatment on liver 
histology a prospective long-term treatment study with glycyrrhizin should be performed 
in Europe. 
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Abstract 
Intravenous glycyrrhizin has been llsed in Japan for the treatment of chronic hepatitis for 
more than 20 years. Nevertheless, only brief reports of its pharmacokinetic profiles after 
multiple intravenous doses in small numbers of Japanese patients have been published. 
The present study compared these Japanese data with the pharmacoklnetic characteristics 
of glycyn'hizin after single and multiple intravenous doses in 35 European patients with 
cln'onie hepatitis C infection. 
We administered SO, 160, or 240 mg glycyrrhizin 3 times/week or 200 mg glycyrrhi-
zin 6 times/week for 4 weeks. Twenty-four-hour pharmacokinetic assessments were 
performed on day I and on or around day 14. Glycyrrhizin levels were determined by high-
performance liquid chromatography. 
The mean (±SD) volume of distribution at steady state on day I in the SO, 160,200 and 
240 mg groups were 67±11; 62±13; 54±7 and 66±S mLlkg, respectively. The respective 
terminal elimination half-lives on day I were 7.7±2.8, 1O.I±1.4, 9.0±2.3, and S.6±2.1 
hours. The area under the curve (AVC) increased linearly with doses :0; 200 mg (r=0.67, 
p<O.OOI). No significant differences between day I and day 14 were found in any dose 
group, with the exception of AVC in the 200 mg group, whieh was significantly higher on 
day 14 compared with day I (p=O.03). Comparing the European and Japanese data, the 
mean (±SD) AVC was 289±244 pg*h/ml for the fonner and 402±372 pg*h/ml for the 
latter; the half-life was 8.2±2.6 versus 8.S±9.0 hours; and the total clearance was 7.6±3.6 
versus 8.5±5.7 mlIh/kg. 
Thus our pharmaeokilletic data are comparable to those from Japan. Glycyrrhizin's 
pharmacokinetics are linear up to 200 mg. Drug accumulation is seen after 2 weeks of 
treatment with 200 mg administered 6 times/week. 
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Introduction 
Glycyrrhizin, extracted from the roots of the plant Glyc)'l'l'hiza glabra (liquorice), has 
been used as a treatment for chronic hepatitis in Japan for more than 20 years.! According 
to information from the manufacturer, Minophagen PluU'maceutical Co., Ltd. (Tokyo, 
Japan), tens of millions of ampoules Stronger Neo-Minophagen" C (SNMC) containing 2 
mg of glycyrrhizin per ml arc used mmually for this indication in Japan. 
Glycyrrhizin is a conjugate of one molecule of glycyrrhetinic acid and two molecules of 
glucuronic acid (Figure 1). Suzuki e1 al. reported that intravenously administered glycyrrhizin 
lowered the scmm transaminase levels significantly in patients with chronic hepatitis.2,3 Arase 
et al. reported that in Japanese patients with chronic hepatitis C infection, long-term treatment 
with glycyrrhizin prevented the development of hepatocellular carcinoma when alanine 
aminotransferase (ALT) normalizes.' Intravenously administercd glycyrrhizin is metabolized 
in the liver by lysosomal P-D-glucuronidase to 3-mono-glucuronide-glycyrrhetinic acid. The 
metabolite is excreted with bile into the intestine, where it is metabolized by bacteria into 
glycyrrhetinic acid, which can be reabsorbed (Figure I).' 
A Medline search of the literature from January 1966 to July 1999 using the key 
words glycyrrhizin(e) and pharmacokinetics yielded a small number of Japanese studies 
involving 10 or less patients. These studies described the pharmacokinetic profile of 
glycyrrhizin after multiple doses at a single dose strength in patients with acute and 
chronic hepatitis and CllThosis of different causes.6.9 In these patients, the total body 
1) In liver: liver lysosomal p-D-grucuronidase 
.:~:" ~ 
:'.ip" .. 
"r~ 
'i'-r' 
.~.'::" ~ "I.:-~" .. 
·!H' 
2) In intestine: bacterial P-D-glucuronidase 
2 w9'" 
.. ..... . 
glycyrrhizin 18-p-glycyrrheti nic acid ITPno-p-D-gluctJrOflide 18-p-glyc.yrrheti nic acid 
Metabolism after intravenous administration of glycyrrhizin. Glycyrrhizin is metabolized in the liver by lysosomal P-D-gtucuronidase 
to 3-mono-glucuronide-glycyrrhetinic acid; 3-mono-gtu(uronide-glycyrrhetinic acid is excreted with bile into the intestine where it is 
metabolized by bacteria to glycyrrhetinic add that can be re-absorbed (enterohepatic cycle). 
Figure 1 
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clearance was inversely correlated with SCHllll ALT level (r=-0.7, 1'<0.05), suggesting a 
correlation of phannacokillctic variables with hepatic fUllction. 
We conducted a Phase Tm clinical trial in Europe to evaluate the dose-dependent pharma-
cokinetics, safety and efficacy of glycyrrhizin treatment. The safety and efficacy results have 
been reported elsewhere. 10 The study reported here was performed to compare the Japanese 
data with pharmacokinetics of increasing doses of glycyrrhizin in European patients. 
Patients and Methods 
Only patients with c1n'Onic hepatitis C infection, with a positive hepatitis C vims RNA 
titer, serum ALT at least 1.5 times the upper limit of normal (ULN), and findings on liver 
biopsy consistent with mild to moderate liver fibrosis 01' cinhosis were included. Patients 
were not eligible for inclusion if they had other causes of liver disease, decompensated 
cirrhosis (Child-Pugh score> 7) or hepatocellular carcinoma. 
The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The protocol was approved by the Medical Ethical Committee of the University 
Hospital Rotterdam and all patients gave their written informed consent. 
Study treatme1lt 
Glycyrrhizin was given as SNMC, a clear solution for intravenolls use, conslstmg 
of 2 mg glycyrrhizin, I mg cysteine and 20 mg glycine per ml in physiological saline 
solution. Patients received 80, 160 or 240 mg intravenous glycyrrhizin 3 times/week or 
200 mg intravenous glycyrrhizin 6 times/week for 4 weeks. The medication administered 
3 times/week was given by drip infusion over 15 to 20 minutes in a total volume 0[220 ml. 
The infusion line was then flushed with 25 ml sodium chloride (0.9%). The medication 
given 6 times/week was administered undiluted into a peripheral vein over 3 to 5 minutes. 
Pharmacokil1etic measurements 
Pharmacokinetic measurements were obtained on the first day of treatment and on or around 
day 14. Patients were not allowed to consume food or drink (except water) after 11.00 p.m. 
of the night before pharmacokinetic measurements were to be taken. Food was allowed 
4 hours aftcr administration of medication, and water was allowed as required. Patients 
remained semirecumbent from 0.5 hours before until 4 hours after receiving medication. 
Blood sampling 
An indwelling cannula was placed in one arm for blood sampling; medication was admini-
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stered in the other ann. Before sampling, approximately I ml blood was discarded. Ethylene-
diamine tetraacetic acid-blood samples (7 mI) were collected at the following times: before 
administration of medication and at 0, 5,15,45,60,90 minutes, 2, 4, 6, S, 10, 12, 16, IS and 
24 hours after administration of medication (at time 0, all the medication was administered). 
Samples were stored on ice, and plasma was separated within one hour by centrifugation 
(40 C and 3000 g for 10 min). Plasma samples were stored at -200 C until analyzed. 
High-Pe/Iannonee Liquid C!/lvlIlotogmphy 
Plasma samples were analyzed by a validated high-performance liquid chromatographic 
(HPLC) method modified from Raggi et 01 .. II Fifty III propylparaben (25 mg/I internal standard 
solution) and 2 mlmethanol were added to 500 It! plasma. After mixing and centrifugation, 
the supernatant was decanted into another test tube and evaporated at 40° C with flushing 
nitrogen. The residue was dissolved in 500 J.l1 acetonitrile/citrate (lSO:320) buffer (0.1 moIn, 
pH 2.S). After vortexing and centrifugation, 20 J.l1 of the supernatant was injected into the 
HPLC-system. The extract was separated on a ChromSpher-5 CS column (200 x 3 mm; 5 
J.un particles) with n acetonitrile/citrate buffer at a flow of 0.6 mllmin at ambient temperature. 
Detection was by ultraviolet absorption at 250 nm with a diode array detector. 
As validated in our laboratory, the assay was lineal' over a range of at least 0.5-150 
mg/l. The limit of quantification was 0.5 mg/l. Day-to-day variations wcre less than 2% at 
concentrations of>30 mg/I and Icss then 5% in the lower range (around Img/I). 
Plwl'lIlacokinetic Analysis 
Weighted least-squares regression analysis, with 1/yl as a weighting factor for each data 
point, was pelfonned using Topfit version 2.0 to analyze the plasma concentration-time 
data for each paticntY We calculated the maximum concentration (CUll,)' total clearance 
(CI,o')' distribution volume of the steady state (V), area under the curve (AVC) from time 
zero to infinity, and tcrminal elimination half-life (t~~). 
Data analysis was based on a weighted 3-compartment disposition model, which was 
deemed the most appropriate model based on visual inspection and minimized residuals. 
Statistical Analysis 
Statistical analysis was performed lIsing Stata 5.0 software (Stata Corporation, college 
Station, Texas, USA). Results are given as mean ± SD. Comparisons between groups were 
conducted using the Kruskal-WalIis test; if 1'<0.05 the Mann-Whitney test was used to 
perform further pairwise comparisons betwcen groups. Differences within groups were 
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assessed with the Wilcoxon signed-rank test. Spearman conelation coefficients were used. 
Significance was set at p=O.05 (two-sided) for all tests. 
Results 
The baseline characteristics of patients are shown in Table I. The four groups were comparable 
in terms of all characteristics except basclineALT value, which was significantly lower in group 
receiving 240 mg 3 times/week than in the gronp receiving 200 mg six times/week (p=0.02). 
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Chromatogram of a plasma sample obtained 6 hours after a single dose of 200 mg glycyrrhizin. The glycyrrhizin peak occurs after 4.7 minutes. 
1.1. = internal standard, PPB = propylparaben 
Figure 2 
Figure 2 shows a chromatogram 6 hours after a single dose of 200 mg glycyrrhizin. 
Figure 3 shows the mean course of the measured plasma concentration on day 1 and day 
14 for the group receiving 200 mg glycyrrhizin 6 times/week. The plasma concentration 
of glycYlThizlll declined according to a 3-compartment model. 
The second of the two phannacokinetic measurements was performed on day 13 in 
1 patient; day 14 in 27 patients; day 15 in 2 patients; and day 16 in 3 patients. 
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Baseline characteristics of the 35 patients per dosage group, 
Dose (number of patients) 80 mg (8) 
frequency of administration 3 times/wk 
male I female 612 
age in years,mean (range) 47 (35-66) 
weightin kg,mean (range) 71 (55-107) 
cirrhosis I noncirrhosis 3/5 
An (UlN),mean (95% el) 3.8 (2.0-5.7) 
• significantly lower than 200 mg 6 x week (p~O.02) 
i 125 
:~ 100 II i 
'" 75 c 
i 50 § 
8 
25 
0 
160 mg (7) 
3 times/wk 
512 
54 (43-60) 
78 (64-94) 
3/4 
3.6 (2.0-5.1) 
240 mg (7) 
3 times/wk 
7/0 
43 (34-59) 
79 (62-119) 
3/4 
2.1*(1.8-2.5) 
I 
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200 mg(13) 
6times/wk 
1112 
50 (39-70) 
79 (63-109) 
7/6 
3.9 (2.2-5.7) 
2 4 6 8 m 12 M m _ W II M 
time (hours) 
Mean measured plasma concentration-time profile of the 200 mg group on day 1 (black line) and day 14 (gray line), dots represent 
standard deviation. Decline of glycyrrhizin according to three-compartment model, 
figure 3 
Results for the pharmacokinetic variables are shown in Table II. A dose-response 
relationship was found for both the C
ma
>; and the AUC. Cma" increased in a log-log plot 
with increasing dosage (day I, r=O.82, p<O.OOI; day 14, r=O.89, p<O.OI); there was no 
significant deviation from linearity. A linear increase in AUe with dose was found only 
for the 80, 160 and 200 mg doses (day I, r=O.67, p<O.OOI; day 14, r=O.57, p<O.002). 
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T.blell 
Pharmacokinetic results (expressed as mean ± standard deviation) by dosage group on days 1 and 14. 
Dose frequency 80 mg l times/wk 160 mg ltimes/wk 240 mg l times/wk 200 mg 6 times/wk 
Day (number of patients) day 1(8) day 14 (7) day 1 (7) day 14 (7) day 1(7) day 14 (7) day 1 (11) day 14 (12) 
Cco< (mgll) 42± 16 31±4 70± 14 72±11 102±7 106± 16 112 ±39 116±40 
V" (01Ill<g) 67 ± 11 66± 10 62± 13 57±15 66±8 63 ±10 54± 7 5J± 14 
AUC (~g'h/01I) 138 ±76 112 ±37 415± 156466 ±2J2 319±66 345± 99 468 ± 210 574± 389 
CI", (mllh/kg) 9.9 ± 3.3 10.8 ± 2.9 5.9 ± 2.5 5.7 ± 2.7 10.3±J.l 9.8±J.2 6.0± 2.6 5.5 ±2.6 
t,,(h) 7.7 ± 2.8 6.2± 2.7 0.1 ± 1.4 10.2± 1.6 8.6 ± 2.1 6.6 ± 2.0 9.0± 2.3 9.1±2.2 
T.ble III 
Total clearance {Cit:!} and half-life (t) (expressed as mean ± standard deviation) for patients with chronic hepatitis and cirrhosis on days 
1 and 14. 
(I", (01llh/kg) 
til (h) 
(hronic hepatitis 
day 1(n=19) day 14 (n=17) 
8.3 ± 3.0 
8.2± 2.2 
8.1 ±J.2 
7.7 ± 2.5 
Cirrhosis 
day1 (n=14) 
7.2±4.0 
9.7 ± 2.3 
day 14 (n=16) 
7.1±4.0 
8.7 ± 2.7 
The mean ± SO V" on day I was between 54±7 and 67±1l ml/kg; the mean CI", 
was between 5.9±2.5 and 1O.3±3.1 mllh/kg; and the mean tIl was between 7.7±2.8 and 
1O.1±1.4 hours. No significant difference was noted on day 1 and day 14 between dose 
groups, except for the significantly higher AUC in the 200 mg group on day 14 compared 
with day I (1'=0.03). All variables showed a strong correlation between day 1 and day 14. 
Table III shows the ClIO! and t~'2 for cinhotic and noncirrhotic patients on day 1 and 
day 14 after combining all dose groups. There were no significant differences between 
cirrhotic and noncirrhotic patients. No correlation could be found between ALT levels at 
baseline and Cltot or (~'i. 
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Discussion 
This study reports the pharmacokinetic characteristics of increasing doses of intravenous 
glycyn·hizin after single and multiple doses in the largest cohort of patients (35 patients) 
studied to date. 
The vm'iation in C
m3x in the 200 mg group appeared to be substantially larger than in the 
other 3 groups (Figure 4). An explanation for tlus observation could be Ihal the 200 mg 
dose was administered by manual direct intravenous injection in 3-5 minutes while the 
olher 3 dosages were administered by dIip infusion in 15-20 minutes; it is likely Ihat the 
slower infusion rate caused a more equal administration of glycyrrhizin between patients 
than injection. 
It is possible that differenl rates of infusion might affect the dose linearity and number 
of compartments. However, in our study, the AUC increased linearly with dose between 
80 to 200 mg, although the 80 and 160 mg doses were administered over 151020 minutes, 
and the 200 mg dose was given over 3 to 5 minutes. The pharmaeokinetic data after both 
adminislralion rales fitted best according to a 3-comparlment model. Thus Ihe difference 
between administration over 3 to 5 minutes or 15 to 20 minutes does not appear to affect 
dose linearity or compartmentalization. 
With glycyrrhizin's half-life of approximalely 9 hours, a dosing interval of 24 hours 
might lead to some accumulalion. Indeed, the AUe for the group receiving 200 mg 
f2 250 
'" 
.s 
x 
e200 
<.) 8 
150 ~ 
, 4-• 100 ~
f ~ , 0 0 0 
50 0 
-t 
0 
80 160 200 240 
dose (mg) 
Calculated maximum concentration (C",) per patient per dose on day 1 and day 14. Line indicates the median per dose for day 1. 
Figure4 
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6 times/week was significantly higher at day 14 compared with day I; after 14 days of 
treatment, the mean ± SD glycyrrhizin concentration before adnuuistration of medication 
was 7.8±11.0 mgt!. 
OUf phannacokinetic data are based upon samples taken between 0 minutes and 24 
hours after administration of medication. We observed a 3-compartment distribution over 
the entire period. Tanaka el al.6 investigated the pharmacokinetic profile of multiple doses 
of intravenously administered glycYlThizin (120 mg) in 8 patients with chronic hepatitis of 
unreported cause, and Yamamura ef aU investigated the same regimen in 4 patients with 
acute hepatitis and 6 patients with ciLThosis (5 of 6 cases were caused by chronic hepatitis 
C infection). In these studies, samples were taken between 2 and 10 hours after drug 
administration. Over this 8-hour period, the investigators observed a l1lonoexponcntiai 
decline in glycyrrhizin, as in our study. 
Combining the phannacokinetic data on the 8 patients from Tanaka et al.6 and the 10 
patients from Yamamura et al.' yields a mean ± SD t",of 8.8±9.0 hours, a CI", of 8.5±5.7 
mlIh/kg and an AVC of 402±372 ;lg*h/ml. These data obtained after multiple doses of 
glycyrrhizin are comparable to those obtained in our study (Table IV). 
Table IV 
Japanese and European pharmacokinelic data after multiple dosages (e)(pressed as mean ± standard deviation) 
Japan (n-18) Europe (n-33) 
AU( for 120 mg (~g'h/ml) 40H372 289± 244 
(I", (ml/h/kg) 8.5 ± 5.7 7.6±3.6 
t" (h) 8.8± 9.0 8.H 2.6 
The til of glycyrrhizin in 3 healthy volunteers has been reported as 3.5 hoursY' 14 
Yamamura el al. observed an increase in t~'i and a decrease in CI
M 
aIllong cirrhotic 
patients compared with noncirrhotic patients. We found no significant differences between 
cirrhotic and noncirrhotic patients (Table Ill). Cl
tot 
and t~~ are pharmacokinetic parameters 
that depend on physiological variables. Therefore it seems logical that a decrease in 
hepatic funclion would lead to a decrease in Cl
lol 
and an increase ill t~~. We did not 
observe such a relationship in the present study, probably because patients with severe 
liver disease were excluded. Mean ALT levels before the initiation of treatment in the 
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Japanese patients were around 300 TUIl, much higher than our baseline ALT levels of 
approximately 3.5 times the ULN (or 150 TUIl). 
Comparisons of pharmacokinetic data between centers should be interpreted cautiollsly. 
Variations in population, stage of disease, dose rate and regimen, sampling frequency and 
duration of observation are all capable of influencing study results. Given these limitations, 
we conclude that our data cOlToborate and strengthen those from the smaller studies. 
The first phase of the 3-compartment model can be explained predominantly by 
distribution of glycyrrhizin. The V" was about 4.5 I per patient which means that gly-
cyrrhizin was confined mainly to the vascular compartment. Glycyrrhizin is not taken 
up in blood cclls.n The second phase can be explained by elimination, predominantly 
through the metabolism of glycyrrhizin to 3-mono-glucuronide-glycyrrhetinic acid in 
the liver by lysosomal ~-D-glucuronidase.5 The third phase can be explained by an 
enterohepatie cycle of glycynhizin, which would extend the elimination.'" 16 
Conclusions 
Glycyrrhizin exhibits linear pharmacokinetics up to 200 mg; steady state kinetics are 
attained after 2 weeks of 200 mg administered 6 times/week. 
Our phannacokinetic data are comparable to the Japanese findings, although we did not 
find a correlation between hepatic function and pharmacokinetics. This difference may be 
explained by our patients having milder liver disease. 
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Chapter 4.1 
Summary 
Backgroulld: Treatment with intravenous glycyrrhizin reduces the progression of 
liver disease caused by chronic hepatitis C (HCV) infection. Glycyrrhetinic acid, a 
metabolite of glycyrrhizin, inhibits the renal conversion of cortisol to cortisone by the 
enzyme II P-hydroxysteroiddehydrogenase in the kidney. The resulting excess of cortisol 
subsequently stimulates the mineralocorticoid receptor, leading to pseudo-aldosteronism 
with hypertension, hypokalemia and evennmlly renin and aldosterone suppression. 
Aim: To evaluate the occurrence of pseudo-aldosteronism after treatment of chronic 
hepatitis C patients with incrcasing doses of intravenous glycyrrhizin. 
Desigll/patiellls: Forty-four HCV patients with chronic hepatitis or compensated cirrhosis 
were treated with intravenous glycyrrhizin 6 x 200 mg / week, or 3 x 240 mg / week or 
3 x a mg / week (placebo) for 4 weeks. 
Measurements: In all patients body weight, blood pressure, and plasma concentrations 
of sodium, potassium, cortisol, DHEA-S (dehydroepiandrosterone sulphate), renin and 
aldosterone were measured before and 0 and 4 weeks after treatment. 
Results: Within the placebo group no significant changes were observed. Within the 1200 
mg group systolic blood pressure was significantly higher at the end of treatment, wltile 
aldosterone was significantly lower; at the end of follow-up these values had returned to 
baseline. The changes from baseline in systolic and diastolic blood pressure at the end 
of treatment were significantly ltigher in the 1200 mg group compared to the placebo 
group. The changes in aldosterone and potassium concentrations at the end of treatment 
increased with increasing dosage although not significantly. 
Conclusion.' Hey patients with chronic hepatitis or compensated cirrhosis show minor 
reversible symptoms of pseudo-aldosteronism after treatment with 1200 mg glycyrrhizin 
weekly for 4 weeks. 
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Introduction 
Glycyrrhizin, a natural compound extracted from the roots of Glycyrrhiza glabra, has been used 
for more than two decades to treat chronic hepatitis in Japan,l Glycyrrhizin is usually given as 
Stronger Neo-Minophagen C (SNMC), a clear solution for intravenous use containing 2 mg 
glycyrrhizin per 1111. SNMC therapy significantly lowers the serum alanine aminotransferase 
(ALT) levels."] ALT normalization, induced by SNMC, reportedly reduces the progression of 
liver disease to hepatocellular carcinoma in patients with chronic hepatitis C infeclion.4 
Glycyrrhizin (GL) is a conjugate of one molecule of glycyrrhetinic acid (GA) and two 
molecules of glucuronic acid. After intravenous administration GL is metabolized in the 
liver by lysosomal P-D-glucuronidase to 3-mono-glucuronidc-glycyrrhetinic acid (3MGA). 
The hnman liver is not able to metabolize 3MGA to GA; 3MGA is excreted with bile into 
the intestine where bacteria metabolize it to GA, which is re-absorbed (Figure 1).5 GA 
inhibits IIP-hydroxysteroiddehydrogenase (II P-HSD).' II P-HSD is an enzyme of which 
two isofol'lns exist. The renal isoform llP-HSD (type 2) has dehydrogenase activity and 
converts cortisol to cortisone; the liver isoform llP-HSD (type I) has oxo-reductase 
activity and catalyses the reverse reaction,7 Inhibition of IIJ)-HSD type 2 leads to increased 
cortisol levels in the kidney. Because cortisol and aldosterone bind with the same affinity 
to the mineralocorticoid receptor, a rise in renal cortisol will result in stimulation of the 
mineralocorticoid receptor, leading to sodium retention, hypokalemia, hypertension and 
eventually to renin and aldosterone suppression (Figure 2).8.9 
1) In liver: liver lysosomal P-D-glucuron!dase 
u 
.. ;>:-~ .. .. 
.!'!--{' 
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;>:-~.. . . 
.!'j-f' 
2) In intestine: bacterial poD-glucuronidase 
2 ... ~.' 
~ 
glycyrrhizin 18-j}-glycyrrhetinicadd rmno-[l-D-glucufonide 18-j}-glycyrrheUnic add 
Metabolism of intravenously administered glycyrrhizin. Glycyrrhizin is metabolized in the human liver to lS-p-glycyrrhetinic-add-mono-
P-D-glucuronide. This is excreted with bile into the inteslinallumen where it is metabolized by bacteria to lS-p-glycyrrhetinic-acid. 
18-p-gtycyrrhetinic·acid is reabsorbed. 
Figure 1 
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Glycyrrhetinic acid inhibits the enzymatic (11 P-HSO type 2) conversion of (ortisol to cortisone in the kidney. This results in an increased 
level of (orlisol, which stimulates the mineralocorticoid receptoT, eventually leading to inhibition of renin formation and, via the 
angiotensin system, inhibition of aldosterone formation. 
Figure 2 
Patients with liver disease have inlpaircd cortisol metabolism;1O there is a negative 
correlation between severity of the liver disease and cortisol levels after ACTH stimulation; 
baseline morning cortisol and dehydroepiandrosterone sulfate levels arc comparable to 
those found for healthy subjects. II 
The aim of this study was to evaluate the occurrence of pseudo-aldosteronism after 
treatment of chronic hepatitis C patients with different stages of liver disease with 
increasing doses of intravenous glycYIThizin. 
Methods 
Subjects 
Patients between 18 and 70 years of age were included if they had: serum antibodies to hepa-
titis C virus (HCY), a positive rcsult for HCY-RNA; serum alanine aminotransferase (ALT) 
at least 1.5 x the upper limit of normal (ULN) (ULN = 41 JUll for males and 31 lUlL for 
females) within the 8 weeks prior to treatment and at the start of treatment; and liver biopsy 
consistent with mild to moderate fibrosis, or cirrhosis with mild to moderate active hepatitis. 
Patients were not eligible for inclusion if they met one or more of the exclusion 
criteria: other causes of liver disease (for example: chronic hepatitis B, alcohol abuse); 
decompensated cirrhosis (ascites), hepatocellular carcinoma or hypokalemia. 
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The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The protocol was approved by the Medical Ethical Committee of the University 
Hospital Rotterdam and all patients gave their written informed consent. 
Treafl1lellf 
Patients \vcre treated with intravenous glycyrrhizin (Minophagcn Pharmaceutical Company 
Tokyo, Japan) 6 x 200 mg 1 week, or 3 x 240 mg 1 week or 3 x 0 mg Iweek (placebo) 
for 4 weeks; the total weekly dosage of glycyrrhizin was 1200 mg, 720 mg or 0 mg, 
respectively. Some of the patients who received 3 x 240 mg 1 week or 0 mg glycyrrhizin 
were treated with 6 x 200 mg glycyrrhizin 1 week aftcr a wash-ont period of at least 6 
months. The follow-up after treatment was also 4 weeks. Patients were not allowed to eat 
liquorice during the study period. Patients were treated on an out-patient basis. 
Assessments 
Body weight, blood pressure, and plasma concentrations of sodium, potassium, cortisol, 
DHEA-S (dehydroepiandrosterone sulphate), renin and aldosterone were measured before 
start of treatment, at the end of treatment and at the end of follow-up. Samples were taken 
between 08.00 and ID.OO a.m .. 
Sodium (reference value 135-145 mmolll) and potassium levels (reference value 3.6-5.1 
Imuolll) were determined by routine assays. Cortisol (reference value: 200-800 nmolll) 
and DHEA-S concentrations (reference values: males, age 40-49: 2.5-14 [lmolll and 
females, age 40-49: 0.8-7 [lmolll) were determined in heparin plasma lIsing immulite I 
(Diagnostic Products Corporation, Los Angeles, CA, USA). Renin (reference value: 5-45 
~lU/m1) was determined in serum by radio immunoassay of generated angiotensin IY 
AJdosterone (reference value: 139-693 pmolll) was determined in serum by a commercially 
available radio immunoassay kit (Coat-A-Count, Diagnostic Products Corporation), 
Statistical analysis 
Results are expressed as mcan ± standard deviation unless stated otherwise. Changes within 
groups were assessed using the Wilcoxon signed-rank test. Changes between the three dosage 
groups, taking into account the fact that the group with 6 x week administration consisted 
partly of patients who also participated in the placebo and 3 x week glycyrrhizin group, were 
compared with ANOVA.1.l Correlation coefficients given are Spearman's. P-values <; 0.05 
(two-sided) were considered to be significant, except for within-group comparisons. These 
were tested at p=O.O 17 (i.e. 0.05/3) in accordance with Bonfel1'oni's principle. 
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Results 
Table I shows the baseline characteristics of all patients. The three groups were comparable. 
Each group consisted of 14 or IS patients; most of the patients were male. The mean age 
was 47 years (range 2S - 70). 
Table II shows the results in detail. The baseline values for the tln'ee groups were 
comparable. Within the placebo group no significant changes were observed. Within the 
720 mg per week group, cortisol was significantly lower at the end of follow-up than at 
baseline (304±IS3 vs. 407±143 nmol/I). DHEA-S was significantly decreased at the end 
of treatment and increased till baseline levels after cessation of treatment. 
Within the 1200 mg per week group, bodyweight was significantly increased with 
respect to baseline at the end of treatment as well as at the end of follow-up (S2.1±14.3 
and SI.7±14.6 vs. 7S.6±1I.S kg at baseline). The systolic blood pressure was significantly 
higher at the end of treatment than at baseline (l42±14 vs. 132±IS mmHg). Renin 
was significantly higher at end of follow-up than at the end of treatment (l2.9±1O.0 vs. 
8A±IIA fIU/mI). Aldosterone was decreased significantly at the end of treatment and 
returned to baseline levels at the end of follow-up. 
Changes with respect to baseline at the end of treatment were compared between 
the three groups. Systolic and diastolic blood pressure showed a significant rise with 
increasing dosage (Figure 3). The decrease in aldosterone and potassiulll increased with 
Table I 
Baseline (haracteristi(s of the patients per dosage group, expressed as mean ± SD. 
group (number of patients) o mg (14) 720m9(15) 1200m9(15*) 
male Ifemale 1311 11 14 12/J 
age (year) 48±7 4J±10 51±9 
height (em) 178±8 173±7 175±8 
weight (kg) 84±14 78±16 79±11 
cirrhosis / noncirrhosis 6/8 6/9 8/7 
All (upper limit of normal) l.1±l.S 2.S±1.0 3.7±2.7 
systolic blood pressure (mmHg) 1l1±13 126±12 1l2±15 
diastolic blood pressure(mmHg) 81±9 82±5 79±10 
1(9 patients received 0 rug or 240 rug glycyrrhizin 3 x week at least 6 months before the 6 x week treatment 
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Symptoms of pseudo~aldosteronism after 4 weeks of glycyrrhizin treatment are shown per dosage group, before treatment (BT), at the end of treatment (EOT) and at the end of 4 weeks of 
follow-up (EOF). Results are expressed as mean ± standard deviation unless stated otherwise. Since there were 3 groups, within group comparisons were tested at p = 0.017 (i.e. 0.05/3) in 
accordance with Bonferroni'$ principle. 
Total weekdose o mg (n;14) 720 mg (n;15) 1200 mg (n;15) 
BT EaT EOf BT EaT EOf BT EOT EOf 
bodyweight (kg) 84.4±13.6 85.3±14S 85.0±14.1 78.4±16.0 78.9±15.9 84.4±13.6 78.6±11.5 82.1 b±14.3 81.Jb±14.6 
systolic blood pressure (mmHg) 131±13 125±13 126±15 126±12 130±14 128±13 132±15 142b±14 1l7±24 
diastolic blood pressure (mmHg) 82±9 79±8 80±7 82±5 80±8 79±7 79±10 85±7 81±10 
sodium (mmolll) 140±2 140±1 141±2 141±2 141±2 140±2 141±1 141±2 140±1 
potassium (mmolll) 4.1±0.5 4.1±0.3 4.1±01 4.1±0.5 4.0±0.4 4.0±0.4 4.2±0.3 4.0±0.3 4.2±0.2 
cortisol (nmol/l) 313±125 307±94 309±12l 407±143 313±80 304'±153 305±129 326±95 343±118 
DHEA-S (~molll) 2.1±1.4 1.9±1.1 1.9±1.4 2.8±2.1 2.4'±1.9 2.8'±2.0 1.9±1.4 1.6±1.2 1.7±1.3 
renin (~U/ml)' 15 (6)3) 17 (3.55) 15(519) 13 (6~0) 10 (3,128) 21 (9,120) 11 (315) 4 (0.1 ,41) 8'(2.9,32) 
aldosterone (pmolll)* 177 (39.551) 130 (89,485) 139 (47,532) 222 (30,1177) 136 (25,950) 213 (86,1299) 163 (64,701) 97' (33,302) 172' (61,488) 
J significantly lowerthan before treatment; 
II significantly higher than before treatment; 
( significantly higher than end of treatment 
* median (range) 
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The changes (mean,SEM) from baseline at the end of treatment in systolic and diastolic blood pressure after four weeks therapywilh 0 mg, 
720 mg or 1200 mg glycyrrhizin weekly. 
Figure 3 
0 
-0.1 
-02 II Omg 
'" 
720 m9 
-0.3 
0 1200 mg 
-40 -0.4 
-50 -0.5 
~-'-___________ --J 
. ·0.6 
aldosterone (pglmI) potassium (mmoVl) 
The changes (mean, SEM) from baseline at the end of treatment in aldosterone (left y-axis) and potassium (right y-axis) after four weeks 
therapy with 0 mg, 720 mg or 1200 mg glycyrrhizin weekly. The data suggest that with increasing dosage aldosterone and potassium 
decrease more. Because the variations within the three groups were large, no statistically significant difference was found. 
Figure 4 
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ALT ULN 
The AlT at baseline (expressed as times the upper limit of normal (UlN);UlN ~ 411Un for males and 31 lUll for females) shows a negative 
correlation with the (ortisoll"el at baseline (rho~-O.5, p=O_002) 
Figure 5 
increasing dosage although the changes were not significantly different betwecn the three 
group (Figure 4). The changes in bodyweight, sodiulll, cortisol, DHEA-S and renin did 
not differ significantly between the three groups. 
Cortisol at baseline was negatively correlated with the ALT at baseline (r~-0.5, p~0.002) 
(Figure 5). There was no correlation between the cortisol level at baseline and stage of 
fibrosis. No correlations were observed between ALT at baseline or stage of fibrosis and 
DHEA-S, aldosterone or renin. 
Discussion 
Treatment with 1200 mg glycyrrhizin weekly caused a significant increase in systolic 
blood pressure and bodyweight and a significant decrease in aldosterone; after cessation 
of therapy systolic blood pressure and aldosterone returned to baseline values. These 
observations suggest the occurrence of pseudo-aldosteronism caused by glycyrrhizin 
treatment. The increasing changes with respect to baseline at the end of treatment in 
aldosterone and potassium levels and systolic and diastolic blood pressure with increasing 
dosages (Figure 3, 4) confirm the impression of the occurrence of pseudo-aldosteronism. 
The change in the systolic and diastolic blood pressure was significantly higher in the 
1200 rng group compared to the placebo group. It is likely that the large variations ill 
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outcome within the three groups explain why no significant changes in the aldosterone or 
potassium levels between the three groups were observed. 
At the end of follow-up bodyweight within the 1200 mg group was still higher 
than before treatment. Because all other symptoms of pseudo-aldosteronism returned to 
baseline values it is unlikely that this increased bodyweight is a remainder of pseudo-
aldosteronism. 
To prevent the occurrence of pseudo-aldosteronism in the general population, the 
recommended maximum oral intake is 200 mg glycyrrhizin per day which is 1400 mg per 
week. 14 On basis of our study results we recommend that patients with chronk hepatitis or 
compensated cirrhosis should not be treated with a dose exceeding 1200 mg glycYlThizin 
weekly; at this dosage some minor symptoms of pseudo-aldosteronism occur and if the 
dosage is further increased the symptoms of pseudo-aldosteronism are likely to increase. 
Patients with cirrhosis and ascites have elevated plasma renin and aldosterone levels. 15 
It is likely that tlus secondary aldosteronism, caused by a hyperkinetic circulation in 
decompensated cirrhosis with portal hypertension, will be reinforced by treatment with 
glycYlThizin. In our study only patients with compensated cirrhosis were includcd; nonc of 
these cirrhotic patients had elevated renin or aldosterone levels before treatment. Patients 
using thiazide diuretics, which enhance potassium loss, arc at risk of developing severe 
hypokalemia during glycyrrhizin treatmen!.!6 Hypokalemia, induced by glycYlThizin, 
can cause cardiac arrhythmias, cardiac arrest, rhabdomyolysis with clinical presentation 
of muscle weakness, paraparesis or quadriplegiaY-Z! Therefore, patients with cirrhosis 
and ascites and patients using thiazide diuretics should be monitored carefully during 
glycyrrluzin treatmcn!. In Japan hypokalemia and hypcrtension during glycyrrluzin 
treatment are successfully treated with the mineralocorticoid receptor antagonist 
spironolactone."' 
We observed a negative correlation between ALT levels and cortisol at baseline: the 
severity of liver disease (ALT) was inversely correlated with cortisol. This finding is in 
agreement with the observation reported by McDonald et al .. !! They found a negative 
cOlTelation between the Child-Pugh score (range 5-15) and bascline cortisol levels. 
Because we included only patients with compcnsated cirrhosis (with a Child-Pugh score 
of 5-7) we correlated baseline cortisol levels with ALT and stage of fibrosis at baseline 
instead of the Child-Pugh scorc. Ninety percent of the serum cortisol is bound to thc 
liver derived protein cortisol binding globulin (CBO). In patients with liver disease the 
COB levels are significantly lower than in healthy persons. ll Therefore the most likely 
explanation for the negative correlation between serum cortisol at baseline and severity of 
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liver disease is a fall in hepatic CBO production. To keep the unbound "active" plasma 
cortisol level unchanged total cortisol levels should be lower, which is in agreement 
with am findings that relatively low levels of plasma cortisol were found. On the other 
hand, in rats with liver cirrhosis the activity of hepatic and renal II ~-hydroxysteroid 
dehydrogenase is downregulated;22 this might eventually lead to increased plasma cortisol 
levels. 
The hypothesis that inhibition of the renal conversion of cortisol to cortisone by 
glycyrrhizin might cause a decrease in cortisol metabolism, which would lead to an 
inhibition of the hypothalamic-pituitary-adrenocortical feedback mechanism and thereby a 
decrease in DHEA-S concentrations, was not confirmed in this study; DHEA-S decreased 
only in the lowest GL dose group not in the highest GL group. This could be explained 
by the fact that the rise in cortisol in the kidney dming GL treatment was sufficient 
to stimulate the mineralocorticoid receptor, whereas the actual plasma level of cortisol 
hardly increased during GL treatment so that the decrease in DHEA-S found in the lowest 
GL group might be considered to be a coincidence. 
In conclusion patients with chronic hepatitis or compensated cirrhosis show minor 
reversible symptoms of pseudo-aldosteronism after treatment with 1200 mg glycYIThizin 
wcekly for 4 weeks. 
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Chapter 4.2 
Daily intake of 200 g licorice does not reduce testosterone IeyeIs in men 
Glycyrrhizin, extracted from the roots of Glycyrrhiza glabra is used as flavoring agent 
and as treatment for clu'onic hepatitis c. l A well known side effect of glycyrrhizin use is 
pseudo-aldosteronism.2 Recently Armanini el al. reported in a letter in the New England 
Journal of Medicine that daily oral intake of 500 mg glycyrrhizin significantly reduced 
serum testosterone levels in seven men.3 These authors suggested that the activity of 
l7/3-hydroxysteroid dehydrogenase was inhibited. However, levels of androstenedione 
were not aITected; which should be the case if such an enzyme block would be induced.' 
In order to investigate alternative mechanisms behind the decreased testosterone 
1evels we evaluated testosterone, FSH and LH levels in thirty-five male patients with 
chronic hepatitis C treated with a mg glycyrrhizin, three times per week 240 mg 
glycyrrhizin or 6 times per week 200 mg glycyrrhizin for four weeks. Medication was 
administered intravenously, follow-up after treatment was also 4 weeks. The effects on 
body weight, systolic blood pressure, serum potassium, aldosterone and renin in our 
patients receiving 200 mg glycyrrhizin six times per week were comparable to 
those in the group receiving 500 mg glycyrrhizin daily dcscribed by Annanini 
et a/,3, 5 (data not shown), However, none of ollr groups showed a significant 
change of testosterone, FSH or LH serum levels during the study period 
(Table I). Armanini el al. stated that 500 mg of glycyrrhizin daily is eaten 
by many people,3 However, the mean daily intake of glycyrrhizin in the United 
Table I 
Serum testosterone, FSH and lH concentrations in male chronic hepatitis C patients before treatment (BT) with 0 mg, 3 times 240 mg or 
6 times 200 mg glycyrrhilin per week,at the end of treatment (EOT) and atthe end of follow up (EOF). 
Within none of the groups a significant change of testosterone, FSH or tH serum levels during the study period was observed. 
Resu!ts are expressed as mean ± standard deviation. 
Treatment week dose Omg(n=12) 720mg(n-ll) 1200 mg (n-12) 
Hormone (ref. valu. male) BT EOT EOF BT EOT EOF BT EOT EOF 
Testosterone 
(nmolll) (10-30) 29±7 29±6 29±6 26±8 26±9 24±7 28±8 30±8 27±8 
fSH (U/I) (2.0-7.0) 7±5 7±5 8±5 7±7 7±7 7±8 8±6 9±6 9±6 
LH (U/I) (1.5-8.0) 4±3 6±4 6±4 4±3 4±2 5±3 6±3 6±4 6±4 
70 
Side effects 
Kingdom, USA and Belgium is I, 3 and 5 mg per person, respectively. Depending on the 
quality of confectionery 1 g of licorice contains approximately I mg glycYlThizin. 
We conclude that daily administration of 200 mg glycyrrhizin does not inflnence 
testosterone levels. Therefore, the occurrence of reduced serum testosterone levels due to 
daily intake of 200 g licorice is unlikely. 
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Chapter 5.1 
Summary 
Backgmllnd: ALT decrease during glycyrrhizin treatment for chronic hepatitis C might 
be caused by an inhibiting effect on the immune mediated damage of hepatocytes. It is 
unknown whether glycynhizin or its metabolite glycyrrhetinic acid is responsible for the 
ALT decrease. 
Aim: To evaluate the effect of glycynhizin and glycynhetinic acid in vitlv on the 
proliferation of peripheral blood mononuclear cells (PBMCs) of a healthy donor and of 
an untreated patient with chronic hepatitis C. 
Methods: PBMCs were incubated with increasing dosages of glycyrrhizin (I - 1000 
ftg/ml), glycyrrhetinic acid (I - 235 ftg/ml) or dexamethasone; cells were stimulated 
with phytohemagglutinin (PHA) and after three days pulsed with tritium thymidine. 
Proliferation was measured after 16 hours and expressed as counts per minute. 
Results: Increasing dosages of dexamethasone inhibited proliferation. Glycyrrhizin did not 
influence proliferation. Glycyrrhetinic acid turned out to be toxic at higher concentrations 
(100 ftg/ml); it is unlikely that these concentrations can be reached ill vivo. The responses 
afler incubation of the healthy donor's PBMCs were comparable to those of cells of the 
untreated patient. 
COIlc/usions: This pilot study did not provide support for a role of glycyrrhizin on PBMCs 
nor a clue whether glycyrrhizin or glycyrrhctillic acid is the active molecule with regard 
to ALT dccrease. 
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Intl'o<luetion 
In Japan, glycyrrhizin - extractcd from the roots of the plant Glycyrrhiza glabra (licorice)-
has been used for the treatment of chronic hepatitis for more than 20 years. I Glycyrrhizin 
treatment significantly reduces alanine aminotransferase (ALT) levels in patients with 
chronic hepatitis C.2,) ALT normalization induced by long-term intravenous glycyrrhizin 
treatment (median 10.1 years) prevented the development of hepatocellular carcinoma 
in chronic hepatitis C patients in Japan.4 After intravenous administration glycyrrhizin 
is metabolized in the human body to glycyrrhetinic acid;5 after oral administration 
glycyrrhizin is metabolized to glycyrrhetinic acid in the iutestinal lumen before 
absorption,' hardly any glycynhizin will be taken up in the body.' 
It is unknown whether glycyrrhizin, glycyrrhetinic acid or both molecules are 
responsible for the ALT decrease / ALT nonnalization in chronic hepatitis C patients. 
Both glycyrrhizin and its metabolite glycyn-hetinic acid are pharmacologically active 
substance.8 If glycynhizin is the active substance with regard to inducing ALT decrease 
intravenous administration is essential, if glycyrrhetinic acid is the active substance oral 
administration may also be effective. 
There is some evidence that glycyrrhizin inhibits immune mediated damage of 
hepatocytes;" 10 glycyrrhizin reportedly induced apoptosis of T-lymphocytes. 1I We 
evaluated in this ill vitro snldy the effect of increasing dosages of glycynhizin and 
glycyrrhetinic acid on proliferation of peripheral blood mononuclear cells of a healthy 
donor and of an untreated hepatitis C vims (HCY) patient. 
Material & methods 
Peripheral blood mononuclear cells (PBMCs) from an untreated HCY-patient and from 
a healthy donor were separated from heparinized blood by Ficoll-Hypaque gradient 
centrifugation. Cells were seeded into 96-well round bottom microtitre culture plates 
at I x 10' cells / well in the presence of phytohemagglutinin (PHA) (I [lg/ml) (Sigma, 
Zwijndrecht, the Netherlands). Cells werc at the same time incubated with medium 
(negative control), dexamethasone (0.1, I, 10 or 50 [1M, positive control), glycYIThizin (I, 
5,10,50, 100,500,1000 flg/ml) or glycyrrhetinic acid (1,5,10,50,100,235 [lg/ml). 
Glycyrrhizin (glycyrrhizic acid ammonium salt, Fluka Chemie, Steinheim, Switzerland) 
was dissolved in phosphate buffer saline (PBS) (Sigma, Zwijndrecht, the Netherlands) 
by lowering the pH to 4 followed by pH normalization to 7.6; 18f3-Glycyrrhetinic acid 
(Fluka Chemie, Steinheim, Switzerland) was dissolved in dimethyl sulphoxide (DMSO) 
(Sigma, Zwijndrecht, the Ncthcrlands) and subsequently further diluted with Roswell 
75 
Chapter 5.1 
Park Memorial Institute culture medium (RPMI) (Gibco BRL, Breda, the Netherlands) 
with 10% human serum (RIOH); dexamethasone (di-Na-phosphate) (pharmacy AZR, 
Rotterdam, the Netherlands) was dissolved in RIOH. 
After three days of incubation, cultures were pulsed with 0.25 flCi 'H-thymidine 
(Amersham, Breda, the Netherlands) and after 16 h the cells were harvested and counts per 
minute (cpm) determined using a scintillation counter (Beckman [nstmments, Leusden, 
the Netherlands) Tests were performed in triplicate; each assay was repeated three times. 
Results 
Figure I a-c shows the results for the healthy donor and the naive HCV patient. The 
PBMCs of the untreated HCV patient reached higher levels of 'H-thymidine incorporation 
after stimulation compared to the healthy donor. The responses after incubation with 
increasing concentrations dexamethasone, glycyrrhizin and glycynhetillic acid of the 
PBMCs of the healthy donor were comparable to those of the naive HCV-patient. 
Increasing dosage of dexamethasone inhibited the proliferation of the PBMCs. The 
addition of increasing dosages of glycyrrhizin had no effect on proliferation. Up to 
50 flg/ml the addition of glycYIThetinic acid did not influence proliferation. At higher 
concentrations (100 flg/ml and 235 flg/ml) proliferation lVas almost completely inhibited. 
Viability tests with trypan blue revealed that at these concentrations the cells were dead. 
Discussion 
We performed this ill vitro study to evaluate whether increasing dosages of glycyrrhizin or 
glycyrrhetinic acid could inhibit the proliferation of PBMCs. 
Treatment of chronic HCV patients with corticostcroids reduces ALT levels and 
increase HCV-RNA levels.I' A reported mechanism of action of glucocorticoids is the 
induction of apoptosis in human monocytesY Treatment with glycyrrhizin reduces or 
IlormaHzes ALT without influencing the viralload,2 Glycyrrhizin is a conjugate of one 
molecule of glycyrrhetinic acid and two molecules of glucuronic acid; glycyrrhctinic 
acid has a steroid like structure. It might thereforc be possible that glycyrrhizin or 
glycYlThetinic acid act in the same way as corticosteroids by inhibiting the immune 
mediated damage of liver cells. 
Dexamethasone was successfully used as a positive control: a dose dependent inhibition 
of proliferation was observed. Incubation with glycYlThizin did not influence the 
proliferation of PBMCs. The plasma levels of glycyrrhizin in HCV patients treated with 
the maximal recommended therapeutic intravenous dosage (=200 mg glycyrrhizin daily) 
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a 
b 
( 
PHA induced proliferation expressed as counts per minute (cpm) of peripheral blood mononuclear cells of a healthy donor (gray bars) and 
an untreated HeV-patient (white bars) after incubation with increasing dosages of dexamethasone (a), glycyrrhizin (b) and glycyrrhetinic 
add (el. 
Figure 1 a-c 
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were between 0.5-200 mg/!." Therefore we used in this ill vi/IV study concentrations of 
I, 5, 10, 50, 100, 500 and 1000 J.lg/ml glycyrrhizin. 
Glycyrrhetinic acid inhibited proliferation almost completely at higher concentrations 
(2 100 J.lg/ml), tIus was a cytotoxic effect. Plasma concentrations of glycYlThetinic acid 
after intravenous treatmcnt with 120 mg glycyrrhizin were between 0.5-1.7 flg/ml." 
After oral administration of glycYIThizin the plasma levels of glycyrrhetinic acid are Icss 
than 0.2 ~lg/m1. 16 Based upon these literature data it is unlikely that after intravenous 
administration of 200 mg glycyrrluzin plasma levels of more than 100 J.lg/m I are reached, 
indicating that the inhibitOlY effcct of glycyrrhetinic acid observed ill vi/IV is most likely 
not the explanation for the ALT lowering cffect during glycyrrhizin treatment ill vivo. 
Oh e/ ai. reported that glycyrrhizin induced apoptosis in mice splcnocytes and 
thymocytes ill vitro as well as in vivo. l ) We used PBMes to evaluate the effect of 
glycyrrluzin and glycyrrhetinic acid on proliferation ill vi/IV. Probably PBMCs are not the 
most appropriate cells to evaluate the effect of glycyrrhizin and glycyrrhetinic acid on the 
immune system; splenocytes or Kupffercells from the liver might be a more appropriate 
choice. 
Conclusions 
This pilot study did not provide support for a role of glycyrrluzin on PBMCs nor a 
clue whether glycyrrhizin or glycyrrhetinic acid is the active molecule with regard to 
ALT decrease. Further investigation is warranted to determine whether glycyrrhizin or 
gIycYlThetinic acid acts as an inhibitor of immune mediated damage in cln'01UC hepatitis 
C infection and whether glycyrrluzin or glycyrrhetinic acid is the active substance with 
regard to ALT decrease ill vivo. 
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Summary 
BackglVlIlld: The mechanism by whieh glycYIThizin lowers ALT without affecting viral 
replication has not yet been established. There are many i11 vitro and animal snldics which 
suggest an array of different mechanisms. 
Aim,' To gain some insight into the mechanism of action of glycyrrhizin in humans treated 
with glycyn·hizin. We evaluated whether glycyn'hizin might act by its interference with 
cortisol metabolism, inhibition of soluble vascular adhesion protein-I (s-VAP-I) formation, 
increasing antioxidant capacity of plasma or by acting as an immullomodulatol'. 
Methods: Forty-four patients with chronic hepatitis C or compensated C cirrhosis were 
treated with intravenous glycyrrhizin 6 x 200 mg / week, or 3 x 240 mg / week or 3 x 
o mg / week (placebo) for 4 weeks. Plasma concentrations of ALT, cortisol, DHEA-S 
(dehydroepiandrosterone sulphate), s-VAP-I, IFN-y, total antioxidant capacity of the 
plasma and total number of leukocytes were measured before and at the end of treatment, 
and 4 weeks after cessation of treatment. Statistical analysis were pelfol"lned using 
.MANOVA and an analysis of repeated ALT rneasures as a linear function of the other 
variables. 
Results: A trend towards a negative correlation between ALT and cortisol during the study 
period was observed (r=-0.32, p=0.06; 1'=-0.16, p=O.03). We did not lind a significant 
correlation between ALT and the other variables. 
COIlc/usions: ALT reduction induced by glycyrrhizin treatment in patients infected with 
cln'onie hepatitis C has been linked to a subtle elevation of serum cortisol. Further 
investigation of the mechanism of action of glycyrrhizin is warranted before we can state 
that the effect of glycyrrhizin on sel1lm ALT is caused by its interference in corticosteroid 
metabolism. 
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Introduction 
Glycynhizin, a natural compound extracted from the roots of G/ycyrrhiza glabra, has 
been used for more than three decades to treat chronic hepatitis in Japan.! Treatment 
with glycyrrhizin significantly lowers serum alanine aminotransferase (ALT) levels.2, J 
ALT normalization induced by long-term treatment with glycyrrhizin reportedly reduces 
progression to hepatocellular carcinoma in patients infected with chronic hepatitis C:t We 
observed a significant decrease in ALT levels during treatment while HeV-RNA levels 
did not change."' The mechanism by which glycyrrhizin lowers ALT without affecting 
viral replication has not yet been established. There are many ill vitro and animal studies 
which suggest an array of different mechanisms.6 Glycynhizin might have a direct 
protective effect on the hepatocyte. It might stabilize the cell membrane of hepatoeytes 
by preventing penetration by viral particles7 or by reducing cell membrane permeability 
which is increased by immuno-activation during viral infection;s it might also act in the 
cytosol as a radical scavenger.9, 10 Another possibility is that gJycynhizin inhibits immune-
mediated cytotoxicity against hepatocytes by suppressing T-cell-mediated cytotoxicityJ[ 
or by inhibiting NFKB binding activity;" NFKB is a transcription factor which seems to 
playa key role in the regulation of immune cell fUllctions. lJ 
The aim of tltis study was to gain some insight into the mechattism of action of 
glycyrrhizin ill vivo in humans. We evaluated four potential mechanisms of action in our 
patients treated with glycyrrhizin: 
I. Exogenously administered corticosteroids significantly rednce ALT levels in patients 
with cluonic viral hepatitis without viral clearance.!4 The glycyrrhizin metabolite 
glycyrrhetinic acid inhibits the enzymatic (ll~-hydroxy-steroid-dehydrogenase) 
conversion of cortisol to cortisone in the kidney:!5 this may lead to increased 
cortisol levels with inhibition of the hypothalamic-pituitary-adrenocortical feedback 
mechanism and thereby a decrease in dehydroepiandrosterone sulphate (OHEA-S) 
concentration. To evaluate this hypothesis cortisol and DHEA-S leve1s were 
measured. 
2. Vascular adhesion protein-I (VAP-I) is a transmembrane molecule, which is expressed 
among others on endothelial cells within liver sinusoids." s-VAP-I, the soluble form, 
enhances lymphocyte binding to endothelial cells." Recently, it was shown that 
s-VAP-l is most probably identical to an enzyme known as semicarbazide-sensitive 
amine oxidase (SSAO)." s-VAP-I is a sialylated glycoprotein; the sialic acids are 
indispensable for the function of s-VAP-I.IS Glycyrrhizin can inhibit sialylation,19 
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therefore it is possible that glycyrrhizin inhibits the formation of active s-VAP-1. To 
evaluate this hypothesis s-VAP-Ilevels were measured. 
3. Hepatitis C related liver damage is often associated with increased iron storage, which 
elicits free radical-mediated peroxidation.20 Glycyrrhizin can act as an anti-oxidative 
agent according to ill vitro and rat studiesY· 10.21 To evaluate this hypothesis the 
antioxidant capacity of plasma was measured. 
4. It is likely that hepatocyte damage during HCV infection is -at least partly- caused 
by the immune system." Glycyrrhizin can induce apoptosis ofT-lymphocytes," which 
might cause inhibition of immune-mediated damage during HCV-infcction. On the 
other hand it has also been rcported that glycYlThizin induces intelferon-y (lFN-y) 
production;'" 25 if tlus is true the immune system would be stimulated instead of 
inhibited by glycyrrhizin.26 To evaluate the hypothesis that glycYlThizin might act as an 
immunomodulator, the total number of leukocytes and the IFN- y levels (a reflection of 
the Thl cell population) were measured. 
We used blood samples of our patients on glycyrrhizin therapy, to evaluate whether 
there is a correlation between reduced ALT levels on the one hand and changes in cortisol, 
DHEA-S, s-VAP-I, anti-oxidant capacity of the plasma, total number of leukocytes and 
IFN-y levels on the other. 
Material & Methods 
Patients 
Patients between 18 and 70 years with a chronic hepatitis C infection, a positive hepatitis 
C virus-RNA titre, serumALT at least 1.5 times the upper limit of normal (ULN), and liver 
biopsy findings consistent with mild to moderate liver fibrosis or cirrhosis were included. 
Patients were not eligible for the study if they had othcr conditions which caused the liver 
disease, decompensated cirrhosis (Child-Pugh score> 7) or hepatocellular carcinoma. 
The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The Medical Ethical Committee of the University Hospital Rotterdam approved 
the protocol and all patients gave their written informed consent. 
Treatment 
Glycyrrhizin was given as Stronger Neo-Minophagen@ C (SNMC", Minophagen 
Pharmaceutical Co., Ltd., Tokyo, Japan). This preparation is a clear solution for intrave-
nOlls administration, consisting of2 mg glycyrrhizin, I mg cysteine and 20 mg glycine per 
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ml of physiological saline. Patients received placebo or 240 mg glycyrrhizin 3 times/week 
or 200 mg glycyrrhizin 6 times/week for 4 weeks; the total weekly dosage was therefore 0, 
no or 1200 mg glycYlThizin, respectively. Follow-up after treatment lasted also 4 weeks. 
Assays 
Samples were takcn bcfore treatment (BT), at the end of treatment (EOT) and at the end 
of follow-up (EOF). 
ALT was determined by standard assay (reference values: male 41 IU/L, female 31 
lUlL, upper limit of normal). 
For cortisol and DHEA-S assessments heparin plasma samples were taken between 8 -
10 a.m .. Cortisol (reference value: 200-800 nmolll) and DHEA-S (reference values malc, 
age 40-49: 2.5-14 ~lmolll and females, age 40-49: 0.8-7 flmolll) were assayed by means 
of Immulite I (Diagnostic Products Corporation, Los Angeles, CA, USA). Interassay 
coefficients of variation were below 8.5 and 9.1 %, respectively. 
SSAO (s-VAP-I) lVas assessed in serum by a functional assay in which benzaldehyde, 
generated from the substrate benzylamine, was quantitated by high performance liquid 
chromatography with fluorimetric detection after derivatization with dimedoneY The 
coefficient of variation was <7%. 
The total antioxidant capacity of deproteinated blood was determined with a 
spectrophotometric assay that was based on the ability of antioxidants to neutralize the free 
radical of 2,2'-l!zinobis-(3-cthylhenzolhiazoline-6-.sulfonate)(ABTS). First plasma was 
deproteinized by adding an equal volume of 10% trichloroacetic acid. After centrifugation, 
an aliquot of the supernatant was added to a solution of ABTS radicals. The reduction 
of absorption at 734 nm, which reflects ABTS radical consumption, was determined. The 
reduction was related to that of a series of trolox calibration solutions. The antioxidant 
capacity of the deproteinated plasma was expressed as the concentration oftrolox solution 
that has similar antioxidant capacity as the deproteinated plasma sample: TEAC (trolox 
equivalent antioxidant capacity). The coefficient of variation was 5%.28 
Total number of leukocytes lVas determined by routine tests (reference value 
4.0 - 10.0 X 10'/1). 
Levels of IFN-y were determined by ELISA (CLB, Amsterdam, the Netherlands); the 
detection limit was I pg/ml. 
Statistical analysis 
Univariate analyses were petformed using Stata 5.0 software (Stata Corporation, College 
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Station, Texas, USA); multivariate analysis was performed with SAS release 6.12 (SAS 
Institute Inc., Cary, North Carolina, USA). 
Univariate analysis using Mann-'Vhitney's test was performed to evaluate comparisons 
between the three treatment groups; the Wilcoxon tcst \vas used to evaluate significant 
differences within groups. 
The correlation between the change in ALT and the change in other variables (cortisol, 
DHEA-S, SSAO, TEAC, leukocytes and lFN-y) was evaluated by multivariate analysis. 
Only 5 of 44 patients were complete responders (=reached normal ALT levels) at the 
end of treatment; if we were to compare responders (n=5) with nonresponders (n=39) 
information about partial ALT response would be lost. Therefore we chose to evaluate the 
correlation/dependency between ALT and the other variables by: 
1. A multiple analysis of variance (MANOVA) taking into account the repeated measures 
design of the study. As a result, the correlation matrix for responses (and especially the 
correlation between ALT and the other responses) was adjusted for dose and time. 
2. An analysis of the repeated ALT measures at the end of treatment and at the end of 
follow-up as a linear function of the other measurements adjusted for dose, time and 
baseline levels of all responses. 
Results 
The baseline characteristics of the patients are shown in Table 1. Each treatment group 
consisted of 14 - 15 patients; the median age was 47 years (range: 25-70). Most patients 
(85%) had not responded to interferon or interferon / ribavirin combination therapy. 
Table II shows the median (0.05, 0.95 percentile) values for ALT, SSAO, TEAC, total 
number of leukocytes and IFN-y before treatment, at the end of treatment and at the end of 
follow-up per dosage group. Cortisol and DHEA-S values are shown in chapter 4.1 (Table 
II, page 61). 
Univariate analysis revealed that groups were comparable at baseline except for IFN-y 
which was significantly lower in the 1200 mg group compared with the two other groups 
(p=0.03). This statistically significant difference is due to the use of another batch for IFN-y 
determination of the 1200 mg group; clinically the IFN-y values did not differ significantly. 
ALT levels at the end of active treatment were significantly lower than before treatment 
(p=0.002); at the end of follow-up the ALT levels had returned to baseline. At the end 
of treatment 5 patients (2 of the 720 mg group and 3 of the 1200 mg group) had normal 
ALT values; 10 patients had ALT levels above normal but less than 1.5 times ULN (2 of 
the placebo, 4 of the 720 mg and 4 of the 1200 mg group); in another 3 cases the mean 
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Baseline characteristics of all 44 patients 
placebo 1720 mg 11200 mg 
male I female 
age (year) # 
cirrhosis! noncirrhosis 
previous interferon yes! no 
ALT (upper limit of normal)# 
HCV-RNA 10'gen.eq.#' 
genotype-II non-l 
# median (0.05,0,95 percentile). *genome equivalent 
14115115 
36/8 
47 (34,66) 
20124 
38/6 
2.5 (1.5,6.7) 
10.7 (1.2,51.4) 
22122 
:Mechanism 
percentage decrease in ALT at the end of treatment was more than 50% while ALT was 
more than 1.5 times ULN. Within the 720 mg group DHEA-S was significantly decreased 
at the end of treatment and increased to baseline levels after cessation of treatment. None 
of the other variables changed significantly during the study period. 
For multivariate analysis all variables except s-VAP-I were transformed by means of a 
natural logarithm to achieve a better approximation of the normal distribution. We found 
a trend toward a negative con'elation between ALT and cortisol. Analysis according to the 
firsl method (MANOVA) resulted in r=-0.32, p=0.06. Analysis according to the second 
method resulted in r=-0.16, p=O.03. Multivariate analysis of the fixed effects (second 
method) showed a borderline significant positive correlation (r=0.6, p=0.05) between 
ALT and TEAC. We did not observe a significant correlation between ALT and DHEA-S, 
vascular adhesion protein (s-VAP-I), total number of whitc blood cells (leukocytes), or 
IFN-y. Table lIT shows the results of the multivariate analysis. 
Discussion 
Glycyrrhizin treatment significantly reduced ALT levels in patients with chronic hepatitis 
C. However, the average cortisol levels remained unchanged during the study period; only 
after multivariate analysis did a trend toward a negative correlation between ALT and cortisol 
during glycyrrhizin treatment become clear. This trend might support the hypothesis that 
the mechanism of action of glycyrrhizin is indirect by increasing endogenous cortisol levels. 
Glycyrrhetinic acid, a metabolite of glycyrrhizin, inhibits the cnzymatic (ll~-hydroxy-
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steroid-dehydrogenase) conversion of cortisol to cortisone;15 this may lead to increased 
cortisol levels. These increased cortisol levels might be responsible for ALT decrease. 
Table III 
The results per parameter (multivariate analysis) in relation with AlT (In). 
We observed a trend to a negative correlation between All and (ortisol and a borderline positive significant correlation between All and TEAL 
General linear Models MANOVA Solution (or fixed effects (MIXED) 
Correlation coefficient p-value Estimat. of .. ffeet standard error p-valu. 
Cortisol (In) -0.32 0.06 -0.16 0.07 O.QJ 
DHEA-S (In) 0.21 0.24 0.06 0.09 0.5 
s-VAP-l 0.14 0.4 0.0002 0.0002 0.4 
TEAC (In) -0.02 0.9 0.6 0.3 0.05 
leukocytes (In) 0.08 0.7 0.08 0.1 0.6 
IFN-y (In) -0.05 0.8 0.08 0.1 0.5 
(In) ~ natural logarithm 
At baseline we observed a negative correlation between ALT levels and cortisol: 
the severity of liver disease (ALT) was inversely correlated with cortisol (chapter 4.1, 
Figure 5). Multivariate analysis revealed that during glycYlThizin treatment this negative 
correlation remained. Therefore another explanation for the trend toward a negative 
correlation between ALT and cortisol might be that an improvement in liver function 
might lead to higher levels of cortisol binding globulin (CBG) and cortisol. In patients 
with liver disease the CGB levels are significantly lower than in healthy individuais,29 
while cortisol levels arc also lower although not significantly.JO Hepatocytes contain the 
enzyme II ~-hydroxysteroid-dehydrogenase type I which catalyzes the conversion of 
cortisone to cortisol; this enzyme is downregulated in cirrhosis. 3! Improvement in liver 
function might therefore lead to higher CBG and cortisol levels. If this is the case the trend 
to a negative correlation bet ween ALT and cortisol would be explained by two phenomena, 
independent of each other but both related to improvement in liver function. 
As reported in chapter 4.1, a clinically significant increase in plasma cortisol levels 
would lead to inhibition of the hypothalamic-pituitary-adrenocortical feedback mechanism 
and thereby a decrease in DHEA-S levels. If this had occurred we should have observed a 
negative correlation between ALT and cortisol and a positive correlation between ALT and 
88 
00 
'-0 
Table II 
The results before treatment (BT), at the end of treatment (EDT) and at the end offollow-up (EOF) per dosage group. Cortisol and OHEA-S values are shown in chapter 4.1 
(Table II, page 61). Results are expressed as median (0.05,0.95 percentile). (univariate analysis). 
Total weekdose Omg (n~14) 
BT EDT EOf 
ALT (ULN) 3.0 (11,6.8) 3.0 (1.4,5.6) 2.8 (15,5.5) 
SSAO (sVAP-1, mUlL) 567 (285,913) 548 (302,791) 530 (355,890) 
TEAC (~mol/mL) 674 (626,754) 706 (594,782) 672 (550,740) 
Leukocytes x 10'/L 5.6 (2.8,11.5) 5.5 (2.3,8.0) 5.2 (2.1,9.3) 
IfN-y(pg/mU 2.3 (15,11.6) 25 (1.6,113) 35 (1.6,105) 
* significantly lower than before treatment 
# significantly lower than baseline levels of the other two groups (p=O.03) 
720mg(n~15) 
BT EDT EOF 
2.3 (1.6,51) 1.6' (0.9,31) 2.0 (0.9,4.6) 
461 (97,1226) 365 (123,818) 422(102,1027) 
683 (597,794) 679 (551,793) 662 (577,774) 
5.6 (3.0,9.2) 5.4 (2.5, 15.3) 5.4 (2.5, 105) 
2.0 (1.5,55) 23 (15,5.5) 2.1 (1.6,15.9) 
1200 mg (n~15) 
BT EDT EDF 
3.0 (1.6,12.5) 1.6'(0.7,5.2) 2.7(1.3,11.8) 
730 (382,971) 710(300,1193) 670 (358,982 
670 (506,776) 682 (648,778) 694 (559,759) 
5.1 (2.7,9.4) 5.4(2.6,9.1) 5.5(2.4,8.3) 
13# (0.7,3.0) 15 (0.7,3B) 13 (0.7,3.6) 
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DHEA-S. Because we did not observe a positive correlation betwecn ALT and DHEA-S, 
we might conclude that cortisol levels did not increase significantly. 
In this study we did not find evidence to support the hypotheses that a decrease in ALT 
is correlated with a change in s-VAP-I, total number of leukocytes or IFN-y. We therefore 
conclude that glycyrrhizin most likely does not influence s-VAP-Ilevels, total number of 
leukocytes or IFN-y levels. 
If glycyrrhizin would increase the total antioxidant capacity of plasma, a negative 
correlation between ALT and TEAC should be found. Instead, multivmiatc analysis of the 
fixed effects of ALT and TEAC resulted in a borderline significant positive correlation 
(r=0.6, p=0.05). Therefore it is not likely that glycyrrhizin contributes significantly to the 
overall antioxidant capacity of plasma. 
Most studies describing a possible mechanism of action of glyCYIThizin focussed on 
one hypothesis and were conducted in animals or in vill"0.6 This study is unique since 
we used human blood samples of HCV patients before, during and after glycyrrhizin 
treatment. Instcad of focussing at one hypothesis, we evaluated four possible hypotheses 
concerning four different mechanisms of action. 
In conclusion the ALT reduction induced by glycyrrhizin treatment in patients infected 
with cln·Olllc hepatitis C has been linked to a subtle elevation of serum cortisol. This might 
support the hypothesis that ALT reduction is related to inhibition of the conversion of 
cortisol to cortisone by glycyrrlllzin's metabolite glycyrrhetinic acid. Further investigation 
of the mechanism of action of glycyrrhizin is warranted before we can state that the effect 
of glycyrrhizin on serum ALT is cansed by its interference in corticosteroid metabolislll. 
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Discussion 
We started the studies descIibed in this thesis in 1996. At that time the standard treatment for 
chronic hepatitis C was interferon monotherapy; a minority of patients (20%) responded with 
viral clearance and ALT normalization. I So for the patients who did not respond 
different treatment strategies were needed. Although the primary aim of antiviral therapy 
is viral clearance, several long term studies on chronic hepatitis Band C revealed that 
persistent ALT normalization (biochemical remission) was a key prognostic factor for 
reduction of complications, regardless of the presence of viral markers in the senlln.2---l 
Therefore, if viral clearance could not be achieved, the induction of biochemical remission 
(ALT-nonnalization) without viral clearance was considered to be a goal of treatment.s 
There are several mono therapies, which aim at the induction of biochemical remission 
without viral clearance in patients infectcd with chronic HCV, for example ursodeoxycholic 
acid (UDCA) or ribavirin in the western wodd. In Asia, Japan, glycyn-hizin has been used 
as a treatment for chronic hepatitis since 1958.6 
All three therapies significantly rcducc ALT levels during treatmcnt, after cessation 
of therapy ALT levels increase again. During oral UDCA therapy 14% percent of the 
patients reached normal ALT levels, side effects hardly occurred, and until now histological 
improvement after UDCA for chronic HCY has not been reported.1-10 During oral ribavirin 
treatment 29-41 percent of the patients reached normal ALT levels, reversible hemolytic 
anemia occurred in almost all ribavirin treatcd patients and histological liver improvement 
(decreased hepatic inflammation and necrosis) was found after treatment of at least 24 
weeksY-14 During intravenous glycyrrhizin treatment 36% of the patients reached normal 
ALT levels, side effects were minimal, and long-term treatment (median 10 years) with 
glycyrrhizin significantly reduced the progression of chronic hepatitis C to hepatocellular 
carcinoma.) 
Therefore, the efficacy with regard to ALT normalization of glycynhizin and ribavirln 
appears superior to UDCA. The occurrence of side effects seems most obvious 
during ribavirin treatment. The oral way of administration of UDCA and ribavirin is 
more convenient than the intravenous way of administration of glycyrrhizin. However, 
glycYlThizin is the only treatment of which it has been reported that long-termmonotherapy 
induces reduction of progression of the liver disease.3 
For more than 20 years glycyrrhizin was widely used as a treatment for chronic hepatitis 
in Japan and the East Asiatic region but not in EuropeY In 1980 Wildhirt started to use 
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glycyrrhizin for the treatment of chronic hepatitis B, C and compensated post hepatic 
cirrhosis in Germany. After 12 years of experience Wildhirt reported uncontrolled 
prospective studies which showed clinical and biochemical improvement. He was very 
positive about the treatment with glycyrrhizin and considered glycyrrhizin therapy superior 
to interferon, although the data shown in his article did not support this conclusion. IS 
Eisenburg reported in 1992 also a positive effect of glycyrrhizin treatmcnt in German 
chronic hepatitis B patients. 16 A search of the Medline database from 1966 till 1999 
(keywords glycyrrhizin(c), glycyrrhizic acid) did not reveal more data about the usc of 
glycyrrhizin for chronic hepatitis in Europe. Why are there no continuations of these 
positive studies by Wildhirt and Eisenburg described in the international literature? In 
contacts with physicians from Germany they refened to the frequent occurrence of side 
effects (hypokalemia, rise of blood pressure, retention of body fluid) especially in patients 
\vith cirrhosis. However, we could not find published evidence about the occurrence of 
side effects during glycyrrhizin therapy for patients with chronic hepatitis in Germany. 
In chapter 4.1 of this thesis the occurrence of side effects in our patients, with chronic 
hepatitis C or compensated cirrhosis, treated with glycyrrhizin is described. Only minor 
reversible side effects occurred in patients receiving 200 mg glycyrrhizin 6 times per 
week, no reduction of treatment was necessary. So our experience with glycYlThizin 
treatment is not in agreement with the German experience. As discussed in chapter 4.1, 
patients with decompensated cirrhosis are more prone to develop severe side effects 
during glycyrrhizin treatment. Therefore it might be possible that in Germany patients 
with decompensated cirrhosis who were treated with glycyrrhizin, developed severe side 
effects; tlus might be an explanation for the different findings. 
Glycyrrhizin is adnunistered as Stronger Neo-Minophagen C (SNMC"), a clear solution 
for intravenous use which contains 2 mg glycyn'hizin, Img cysteine and 20 mg glycine per 
mL physiological saline.3. 17-21 
In Japan, glycyrrhizin is usually administered daily.J, 17-20 The treatment schedule is not 
standardized. The dosage varies between 40 m]l7, 18 and 100 nll.J, 19,20 After an initial daily 
treatment of 8 weeks the dosage l ' is often reduced to 20-40 ml daily or the administration 
frequency is diminished to 2-7 times per week,3 Long-term treatment appears essential in 
order to reduce the incidence of hepatocellular carcinoma. J 
Daily intravenous administration of medicines is very unusual for the outpatient clinic 
in the Western world. Therefore we started with a 4 weeks placebo controlled feasibility 
study in which glycynhizin was administered three times per week. We found that 56 
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out of 57 patients completed the treatment and that outpatient intravenous therapy was 
more easily accepted than anticipated. This study (chapter 2.1) also revealed that active 
treatment was significantly more effective with regard to the mean percentage ALT 
decrease than placebo. We found that 10% (4/41) of the patients reached normal ALT 
levels at the end of treatment. This is in agreement with the finding of Tsubota et 
al.,'l they found that after tln'ee times per week treatment 17.7% (11/62) of the patients 
reached normal ALT levels. Therefore we conclude that tln'ee times per week glycyrrhizin 
treatment is as effective with regard to ALT normalization in our European patients 
compared with the Japanese patients. 
Arase et al.,3 however, reported that 36% of their patients (30/84) reached ALT 
normalization with daily treatment. Our second study revealed that it is also feasible to 
treat European outpatients with intravenous treatment six times per week. Twenty percent 
(3/15) reached normal ALT values at the end of treatment, which is comparable to the 
results of Arase et al .. 
In conclusion, administration of six times per week is more effective than three 
times per week. This seems logical if the pharmacokinetic parameters of glycyrrhizin 
are considered. With a half-life of approximately 8 hours, (chapter 3) six times per 
week treatment was associated with detectable levels of glycyrrhizin at all times, while 
glycyrrhizin disappeared from the blood with tln'ee times per week administration. 
The aim of glycyrrhizin treatment was to induce biochemical remission (ALT 
normalization) in order to reduce the progression of the liver disease. Only 20% of our 
actively treated patients reached normal ALT levels during glycynhizin therapy (chapter 
2.2). If ALT normalization is necessary to reduce progression of the disease, glycyrrhizin 
therapy might be successful in only 20% of the treated patients. Several studies report now 
that ALT levels need not to be normal to reduce the disease progression; significantly lower 
ALT levels were also associated with a lower incidence of hepatocellular carcinoma.21, 2J 
Glycyrrhizin might be a successful treatment for more than 20% of the treated patients, 
since all treated patients showed a significant decrease of ALT (chapter 2.2). 
In our first clinical study in Rotterdam (chapter 2.1) glycyrrhizin was administered 
via an intravenous (i.v.) cannula in a peripheral vein during 15-20 minutes. In the 
additional study (chapter 2.2) glycyrrhizin was given via a butterfly needle in 5 minutes, 
in accordance with the methodology used in Japan. After completion of glycyrrhizin 
administration the way of venular access (cannula or butterfly needle) was removed. A 
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Jiterature survey revealed that intravenous access by a cannula remained three times 
longer functional than a butterfly needle (49.5 versus 15.4 hours);" extravasation of fluid 
occurred in lout of 71 cases (1.4%) with a cannula compared with 18 out 71 cases 
(25.5%) with a needle;" the bacterial adherence to butterfly needles was less compared 
with a cannula:26 a cannula caused significantly more phlebitis (18.8% versus 8.8% with a 
needle) and butterfly needles were significantly more associated with infiltration (40.1 % 
versus 17.9% with a cannula).27 In conclusion, a cannula remains longer functional and is 
associated with less extravasation and infiltration, whereas a butterfly needle is associated 
with less bacterial adherence and phlebitis. The venular access during glycyrrhizin therapy 
should be functional for maximal 20 minutes so the occurrence of occlusion or phlebitis in 
such a short time will be minimal. We observed in ollr patients no significant differences 
between administration via a butterfly needle or via a cannula with regard to extravasation 
of medication and hematoma at the injection site (chapter 2.2). Therefore based upon the 
literature and our experience we cannot recommend one way of administration above the 
other. 
The mcchanism by which glycyrrhizin induces ALT decrease without viral clearance is 
not known. It is possible that glycyrrhizin or one of its metabolites acts directly protective 
on the hepatocyte, it might also be possible that glycyrrhizin interferes with the immune 
system which causes the damage to the hepatocyte (chapter 5.2). 
It is even unclear whether glycyrrhizin or its metabolite glyeyrrhetinic acid is the active 
substance with regard to ALT decrease (chapter 5.1). 
The elimination half-life of glycyrrhizin is approximately 8 hours (chapter 3); the half-
life of glycyrrhetinie acid is 12-39 hours." Based upon the half-life of glycyrrhizin daily 
administration is warranted to obtain detectable levels in the plasma; for glycyrrhetinic 
acid administration every other day would be sufficient. Our observation that six times per 
week administration was significantly more effective than three times per week, makes 
it likely that glycyrrhizin itself is the active molecule with regard to ALT decrease. If 
glycyrrhetinic acid would be responsible for the ALT decrease, tIn'ee times per week 
administration would suffice. 
At tlus moment the standard trcatment for chronic hepatitis C has become combination 
therapy with interferon I ribavirin.29 Forty-fifty percent of the patients become sustained 
responder (::::::virus is not detectable and ALT is normal six months after cessation of 
therapy). So 50% still does not respond with viral clearance. 
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Glycyrrhizin treatment should be further explored for patients who did not respond 
with viral clearance to standard treatment or patients who are not eligible for or refuse 
treatment with interferon / ribavirin. 
Short-term treatment with glycyrrhizin appeared feasible and effective with regard to 
inducing ALT decrease. A long-term prospective study with glycyrrhizin in European 
patients should be conducted to evaluate the feasibility and the effect on liver histology. 
The treatment schedule should be optimized. 
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Summary 
Chronic hepatitis C infection cun be associated with progressive liver disease that may 
evolve insidiously to cirrhosis and carries the risk of hepatocellular carcinoma. For 
patients who do not respond with viral clearance to standard therapy (intclferon or 
interferon / ribavirin combination therapy), other treatment options should be sought. 
Glycyrrhizin, extracted from the roots of Glycy,.,.iliza glabra, has been used in Japan 
as a treatment for chronic hepatitis for more than 30 years. It induces an alanine 
aminotransferase (ALT) decrease / normalization and thereby reportedly reduces the 
progression of chronic hepatitis C to hepatocellular carcinoma. The fe,v reported clinical 
and phannacokinetic data about the use of glYCYIThizin as a treatment for chronic hepatitis 
come from Japan. Because of its sweet taste glycyrrhizin is also used as a food additive in 
for example licorice. Pseudo-aldosteronism with hypokalemia and hypertension is a well 
described side effect of an excess intake of licorice, caused by glycyn'hizin's metabolite 
glycyrrhetinic acid. The mechanism by which glycynhizin induces ALT decrease without 
viral clearance is unknown (chapter 1). 
Glycyrrhizin given as treatment for dn'onic hepatitis, should be administered 2 till 7 
times per week intravenously. In "'estern Europe it is very unusual to treat out-clinic 
patients with frequent intravenous medication. The studies presented in this thesis describe 
our experience with short-term (4 weeks) glycyrrhizin treatment in European patients. 
We started with a double-blind, randomized, placebo-controlled trial in which 
medication was given 3 times pel' week for 4 weeks (chapter 2.1). Fifty-four patients 
were treated with 0 mg (placebo), 80 mg, 160 mg or 240 mg glycynhizin. The mean 
percentage ALT decrease at the end of active treatment was significantly higher compared 
with placebo, while there was no significant difference between the three active groups 
(6%, 23%, 26%, and 29% for 0 mg (placebo), 80 mg, 160 mg or 240 mg glycynhizin, 
respectively). It turned out to be feasible to treat our out-clinic patients with 3 times pel' 
week intravenous medication. In order to increase the efficacy, we conducted an additional 
open trial in which the efficacy and feasibility of 6 times per week Lv. medication 
administration was evaluated for 4 weeks. 
Chapter 2.2 presents the combined results of these two consecutive trials. Sixty-nine 
out of seventy eligible patients completed treatment according to protocol (compliance 
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99%). The percentage of patients with ALT normalization at the end of treatment doublcd 
after 6 times per week treatment compared with 3 times per week (20% (3115) versus 10% 
(4/41)); due to the relatively small numbers of patients studied, no statistically significant 
difference was found. The mean percentage ALT decrease at the end of active treatment 
was significantly more compared with placebo. while six times per week was significantly 
better than three times per week (6%, 26% and 47% for placebo, three times per week and 
six times per week treatment, respectively). After cessation of therapy ALT returned to 
baseline levels within two weeks. Hepatitis C Vims Ribonucleic Acid (HCV-RNA) levels 
did not significantly change during the study period. There were no clinically significant 
differences between placebo, 3 times or six times per week treatment with regard to the 
occurrence of adverse events. 
Twenty-four hour pharmacokinctic measurements were performed on the first day of 
treatment and on or around fourteen days after start of treatment in 35 at random selected 
patients (chapter 3). The half-life of glycyrrhizin was approximately 8 hours, so with 
six times per week treatment glycyrrhizin was detectable in the plasma at all moments. 
in contrast to three times per week administration. Glycyrrhizin plasma levels declined 
according a three-compartment model with a total clearance of 7.6 mUh/kg. The first 
phase of the tln'ee-compartment model can be explained predominantly by the distribution 
of glycyrrhizin; glycyrrhizin was mainly confined to the vascular compartment. The 
second phase can be explained by metabolism of glycyJ'1'hizin in the liver. The third 
phase can be explained by an enterohepatic cycle of glycyrrhizin, which would extend the 
elimination phase. We did not observe a cOlTelation between severity of liver disease and 
pharmacokinetic parameters. 
We evaluated the occurrence of pseudo-aldosteronism in patients who received 0 mg. 
720 mg or 1200 mg glycyJ'1'hizin per week (chapter 4.1). Only within the group receiving 
1200 mg glycyrrhizin pCI' week minor reversible symptoms of pseudoaldosteronism 
(significant decrease of aldosterone and significant increase of systolic blood pressure and 
body weight) occurred. 
Although a letter in the New England Journal of Medicine, October 1999, reported that 
daily intake of 500 mg glycyrrhizin significantly reduced testosterone levels in men, we 
could not confirm tlus in our male patients. We concluded that our maximum daily dose 
(200 mg glycyrrhizin) does not influence testosterone levels (chapter 4.2). 
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GJycynhizin as well as its metabolite glycynhetinic acid are pharmacological active 
substances. It is unknown which of these molecules is responsible for ALT decrease. In 
a pilot ill vitro study with peripheral blood mononuclear cells (PBMCs) of an untreated 
patient with chronic hepatitis C, we evaluated the effect of incubation with increasing 
dosages of glycyrrhizin and glycyrrhetinic acid on stimulation of these cells. Tltis study 
did not provide support for an effect of glycyrrhizin on PBMCs, nor whether glycyrrhizin 
or glycyrrhethtic acid is the active molecule with regard to ALT decrease (chapter 5.1). 
In order to reveal the mechanism by which glycyrrhizin induces ALT decrease without 
viral clearance, we evaluated the relation of several parameters with the course of ALT 
dming glycyrrhizin treatment and follow-up after treatment in vivo. We found a just 
significant negative cOlTclation between changes inALT and cortisol. Further investigation 
of the mechanism is warranted before we can confirm that the effect of glycynhizin on 
senlluALT is caused by its interference in corticosteroid metabolism (chapter 5.2). 
In conclusion, it is feasible to treat European patients with 3-6 times per week 
intravenous glycyrrhizin for 4 weeks. Treatment induces a significant ALT decrease. Six 
times per week is more effective than three times per week treatment. HCV-RNA levels 
do not change significantly and side effects are minimal and reversible. To evaluate 
the benefit of treatment on liver ltistology a prospective long-term treatment study with 
glycynhizin should be performed. 
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Chronischc hepatitis C infectie is cen progressieve leverziekte die langzaam maar zeker 
kan leiden tot lever cilTose en die cen verhoogd risico op hepatocellulair carcinoom met 
zich mee brengt. Voar patienten die niet reageren met klaring van het virus op standaard 
behandeling (interferon of interferon / ribavirine), is het noodzakelijk dat er andere 
behandelingslllogclijkheden worden gezocht. Glycyrrhizine, afkomstig uit de wortels van 
de plant Glycyrrlriza glabra, wordt al meer dan 30 jaar gebruikt als behandeling voor 
chronische hepatitis in Japan. GlycYlThizine induceert een alanine aminotransferase (ALT) 
dating of nonnalisatie; het is beschreven dat glycyrrhizine behandeling de progressic van 
cen chronische hepatitis C infectie naar hepatocellulair carcinoom remt. Er is cen aanta} 
artikelen over het gebl1lik van glycyrrhizine als behandeling voor chronische hepatitis C 
waarin oak de fan113Cokinctiek beschreven wardt. Deze artikelen kamcn vrijwel allemaa1 
uit Japan. 
Omdat glycyrrhizine cen zoete smaak heeft, wordt het oak gebruikt als smaakversterker 
in voedingsmiddelen, zoals bijvoorbeeld in drop. Pseudo-aldosteronisme met hypokaliemie 
en hypertensie is een goed gedocumenteerde bijwerking van een overmaat aan drop. De 
manier waarop glycyrrhizine een ALT dating induceert zonder klaring van het virus in niet 
bekend (hoofdstuk I). 
Glycyrrhizine dient 2 tot 7 keer per week intravencus te worden toegediend als 
behandeling voor chronische hepatitis. In West Europa is het erg ongebruikelijk om 
poliklinische patienten zo frequent te behandelen met intraveneuze medicatie. De 
onderzoeken in dit proefschrift beschrijven onze ervaring met kortdurende (4 wekcn) 
glycYlThizine behandeling in Europese patienten. 
Wij zijn begonnen met een dllbbel-blind, gerandomiseerd, placebo-gecontroleerd 
onderzoek waarbij de medicatic drie maal per week gedurende 4 weken werd gegeven 
(hoofdstllk 2.1). Vierenvijftig patienten werden behandeld met 0 mg (placebo), 80 mg, 160 
mg of 240 mg glycyrrhizine. Het gemiddelde percentage ALT daling aan het eind van 
de behandeling in de groep behandeld met acticve stof was significant hoger dan in de 
placebogroep; er was geen significant verschil tussen de drie glycyrrhizine groepen (6%, 
23%, 26% en 29% voor achtereenvolgens 0 mg (placebo), 80 mg, 160 mg of 240 mg). Het 
bleek haalbaar te zijn om poliklinischc patiCnten tc behandelen met drie maal per week een 
intraveneuze toediening. Om de effectiviteit van glYCYIThizine te verhogen, hebben we een 
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aanvullend onderzoek uitgevoerd waarin de effectiviteit en de haalbaarbeid van 6 maal per 
week intraveneuze medicatie toediening voor de peri ode van 4 weken werd geevalueerd. 
Hoofdstuk 2.2 beschrijft de gecombineerde resultaten van de twee opeenvolgende 
onderzoeken. Negenenzestig van de 70 geschikte patienten doorliepen het onderzoek 
zoals het in het protocol was voorgeschreven (therapie trouw 99% van de patienten). 
Het percentage paW:;nten met ALT normalisatie aan het eind van de zes maal per 
week behandeling verdubbelde in vergelijking met de drie maal per week behandeling 
(20% (3/15) versus 10% (4/41)); vanwege het relatief kleine aantal patienten werd geen 
statistisch significant verschil gevonden. Het gemiddelde percentage ALT daling aan het 
eind van bchandeling was significant grater in de met glycynhizine behandelde graep dan 
in de placebo groep; zes keer per week was significant beter dan drie keer per week (6%, 
26% en 47% voor achtereenvolgens placebo, drie maal en zes maal per week glycyrrhizine 
behandeling). Na het stoppen van de glycyrrhizine toediening, stegen de ALT waarden 
binnen veertien dagen tot het uitgangsniveau. Hepatitis C Virus Ribonucleic Acid (HCV-
RNA) waarden veranderden aiet significant gedurende de onderzoeksperiode. Er waren 
geen klinisch significantc verschi11en in het optredcn van nevenverschijnsclcn tussen 
placebo, drie maal en zes maal per week glycynhizine toediening. 
Voor het bcpalcn van 24 uut' farmacokinetische parameters van glycyrrhizine werden, 
op de eerste dag van behandeling en op of rondom de veertiende dag na het starten van de 
therapic, bloedmonsters a[genomen van 35 at random gesclccteerde patienten (hoofdstllk 
3). De ha1t\vaarde tijd van glycyrrhizine was ongeveer 8 UUf. Tijdens de zcs maal per weck 
glycyrrhizine behandeling was op elk tijdstip glycyrrhizine te meten in het plasma, dit 
was niet het geval bij de drie maal per week glycyrrhizine behandeling. Glycyrrhizine 
plasma waarden daalden volgens een 3-compartimentsmodel met CCIl totale klaring van 
7,6 mlluur/kg. De eerste fase van het 3-compartimentsmodel kan worden verklaard door 
de verdeling van glycynhizine; glycyrrhizinc beyond zich grotendeels in het vasculairc 
compartiment. De tweede fase kan worden verklaard door de omzetting van glycyrrhizine 
in de lever. De derde fase kan verklaard worden door de enterohepatische hingloop van 
glycyrrhizine, dit praces vertraagt de eliminatie fase. We hebben geen cone1atie gevondcn 
tussen de ernst van de leverzickte en de fannacokinetische parameters. 
We hebben het optreden van pseudo-aldosteranisme geevalueerd in patienten die waren 
behandeld met 0 mg, 720 mg of 1200 mg glycyrrhizine per week (hoofdstuk 4.1). 
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Slechts binnen de groep die 1200 mg glycynhizine per week heeft gehad, traden 
minimale reversibele verschijnselen van pseudo-aldosteronisme op (significante daling 
van aldosteron, and significante stijging van de systolische bloedruk en het gewicht). 
Hoewel een bericht in de New England Journal of Medicine, oktober 1999, venneldde 
dat dagelijkse inname van 500 mg glycyrrhizine de testosteron spiegels van mannen 
significant redllceerde, von den wij dit verschijnselniet in onze mannelijke patienten. Wij 
concludeerden dat onze maximale dagclijkse dosis (200 mg glycyrrhizine) geen invloed 
heeft op de testosteron spiegels (hoofdstuk 4.2). 
Glycyn'hizine en het metaboliet glycyrrhetine zuur zijn beide farmacologisch actieve 
moleculen. Het is onbekend welke van deze twee moleculen verantwoordclijk is vaal' 
de ALT daling. In een orienterend ill vitro onderzoek met perifeer biDed mononucleaire 
cellen (PBMC's) van een onbehandelde patient met c1n'Olllsche hepatitis C en een controle 
persoon, hebben we het effect van incubatie met oplopende doscring glycyrrhizine en 
glycyrrhetine zuur op stimulatie van deze cellen geevalueerd. Wij vonden geen effect van 
glycyrrhizine of glycynhetine zuur op dc PBMC's; er went dus in dit model geen indicatie 
gevonden of glycyrrhizine dan wei glycyn'hetine zuur het actieve stofje is met betrekking 
tot deALT daling (hoofdstuk 5.1). 
am het mechanisme van de door glycyrrhizine ge'induceerde ALT daling zonder 
klaring van het virus te achterhalen, hebben we de relatie tussen het verloop van ALT 
en enkele andere parameters geevalueerd gedurende de behandcling en de follow-up na 
behandeling in vivo. We vonden dat er een negatieve correlatie tussen veranderlngen in 
de spiegels van ALT en cortisol aanwczig was. Verder onderzoek naar het achterliggende 
mechanisme is nodig voordat we kunnen bevestigen dat het effect van glycyrrhizine 
op ALT is veroorzaakt door glycyrrhizine's be'invloeding van het cortisol metabolisme 
(hoofdstuk 5.2) 
Concluderend blijkt het haalbaar te zijn poliklinische patienten in Europa te behandelen 
met 3-6 maal per week intraveneus glycyrrhizine. Behandeling indllceert een significante 
ALT daling. Zes keer per week behandeling is effectiever dan drie maal per week. HCV-
RNA wam"den veranderden niet significant en bijwerkingen waren minimaal en rcversibel. 
Een langdurig onderzoek met glycyrrhizine dient te worden uitgevocrd om het effect van 
de behandeling op Illstologisch Illveau in de lever vast te kunnen stellen. 
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en adviezen waren onlllisbaar voor de tot stand koming van dit proefsehrift. 
Het personeel vall de Clinical Research Unit (Christie, Hanny, Jacqueline, THia, Karin, 
Jean, Leo, Marijke en Juul), onder leiding van Aart Jan vall der Lely en Hans van 
Nunspeet, dank ik VOOI' de ondersteuning bij het behandelen van mijn patienten. Met 
name Ana Alves, dank je weI voor het invullen van de Case Report Forms van de 
aanvullende studie. Cootje van Al1er wiI ik bedanken vaal' haa1' inzet, ze stand altijd klaar 
als ik een aantal senU111l10nsters nodig had va or een extra bepaling. 
Monique Visser, Clinical Research Associate van Kendle, heeft mij tijdens het 
monitoren van het onderzoek veel geleerd over Good Clinical Practice. 
Zander hulp van het secretariaat van de Maag-, Dann- en Leverafdeling was het 
schrijven van dit proefschrift een stuk las tiger geweest. Wil van "Veert en Carin van Vliet 
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dank ik voor hUll ondersteuning bij het uitvoercn van de onderzoeken. Sylvia de Vlaming 
dank ik Vaal' het verwerken van abstracts en artikelen. Zij zorgde cryaor dat ruet aileen de 
deadline wcrd gehaald, maar oak de lay-out netjes vcrzorgd was. 
Mijn collega-arts-onderzoekcrs dank ik voor de gezelligheid. 
Bij het schrijven van een proefschrift is in deze tijd een computer noodzakelijk. Jan 
Boot zorgde ervoal' dat ik beschikte over cen sncl werkende computer en cen compacte 
database wmu'in mijn onderzoeksgegevens ovcrzichtelijk opgeslagcll konden worden. 
De afdcling virologie, onder Iciding van Prof.dr. A.D.M.E. Osterhaus, heeft een 
esscntiele hijdrage geleverd aan dit project. Bart Haagmans en Svcn Bruijns jullie 
inspanning om een mogelijk werkingsmechanisme van glycyrrhizinc aan te tonen, heen 
helaas lliet het gewenste resultaat opgeleverd. Desalniettcmin heel veel dank Vaal' jullie 
medewerking. 
Prof. dr. A. Bast en Guido R.M.M. Haenen van de Universiteit van Maastricht en Robin 
van den Berg, TNO Zeist, wil ik bedanken voor hun bijdrage aan het onderzoek naal' het 
werkingsmechanisl11e van glycyrrhizine. 
Aljan, lief brocl'tje van me, je bent zelf heel druk bezig met een promotie-ondcl'zoek in 
Wales; gaaf dat je naar het vaste land komt am mijn paranimf te zijn. 
Mijn andere paranimf, Pil11 de Ronde, dank ik voor zijn vriendschap. Waar is tach ons 
goede oude studentenleven gebleven? 
Lieve mams en pagie uiteindelijk ligt de basis van dit proefschrift bij jullie. Dank 
jullie wel Vaal' jullie stil11ulatie, vertrouwen en onvoorwaardelijke Hefde. Irene, je bent het 
liefste zusje van de hele wereld. 
Tenslotte wiI ik Jan, mijn grote steun en toeverlaat bedanken. Lieve Jan, je hebt mijn 
leven zoveel rijker gemaakt. Dank je weI! 
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In 1989 werd begonnen met de studie Geneeskunde aan de Erasmus Universiteit 
Rotterdam. Van september 1993 tot september 1994 was zij werkzaam als student-
onderzoekcr op het Laboratorium van Experimentele Chi111rgie, Erasmus Universiteit, 
Rotterdam, onder leiding van Dr. RL. Marquet en Dr. RW.F. de Bruin. Op 20 januari 
1994 werd het doetoraal geneeskunde met Iof afgelegd en op 19 juli 1996 werd het arts-
examen evel1cens met lor bchaald. Van augustus 1996 tot januari 2000 was zij werkzaam 
op de afdeling Maag-, Dann-, en Leverziekten van het Aeademisch Ziekenhuis Rotterdam 
(Dijkzigt). Tijdens deze periode werd onder begeleiding van Prof. dr. S.w. Schalln 
onderzoek velTicht naar gIyeYlThizine behandeling bij paticnten besmet met chronische 
hepatitis C, hetgeen de basis vonnde voor dit proefsehrift. Sinds januari 2000 is zij 
werkzaam als research arts bij Good Clinical Practice te Rotterdam. Zij is getrouwd met 
Jan W. Paul. Samen hebben zij cen ZQon, Jasper. 
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